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“Pain is temporary. 
It may last for a minute, or an hour, or a day, or (even) a year, 
but eventually it will subside  
and something else will take its place. 
If I quit, however, it lasts forever”. 
– Lance Armstrong
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1. Introduction. 
1.1. Metastasis as the major cause of cancer related deaths. 
1.1.1. Incidence and caused of cancer related deaths. 
Population based studies showed that cancer is among the leading causes of death worldwide. 
A recent report of the International Agency for Research on Cancer (IARC) on global patterns 
of cancer related incidence and mortality indicated that in 2012 alone 8.2 million people died 
of cancer and another 14.1 million new cases have been diagnosed [1]. Furthermore, it is 
projected that by 2030 the global cancer incidence will reach 22.2 million causing 13.2 
million deaths and thereby becoming the major cause of morbidity and mortality worldwide 
[2]. The most common cancers are carcinomas, solid tumors arising in epithelial tissues, 
among which five tumor entities account for close to 50% of all deaths related to cancer: lung, 
breast, colorectal, prostate and stomach cancers [1]. Moreover, more than 90% of mortality 
from solid cancers can be attributed to metastasis, defined as the outgrowth of cancer cells in 
organs anatomically distant to the tissue of cancer origin [3]. Despite significant progress in 
cancer treatment, in particular introduction of novel therapeutic agents targeting specifically 
cancer relevant genes (e.g. Trastuzumab, a drug modulating activity of HER2/neu, which 
drives tumor progression in ~20% of breast cancer patients) [4,5], the prognosis for patients 
with late stage (metastatic) carcinomas has not changed over the last four decades with 
majority of patients dying within five years after the initial diagnosis and disease remaining 
largely incurable at this stage [6,7]. Compared to metastatic patients the average survival rate 
is higher in individuals with locally confined tumors (e.g. in breast cancer the expected 5-year 
survival rates estimated at diagnosis for patients with localized and metastatic disease 
amounts to 98.4 or 23.9%, respectively) [7]. Nevertheless, even in early-stage cancer patients 
metastatic lesions can arise after long latency periods. For instance, in breast cancer relapse 
can occur even twenty years after the initial diagnosis and treatment [8]. Consequently, the 
outcome of cancer treatment largely depends on the capacity to prohibit the process of 
metastatic spread or inhibit it at the earliest possible stage.  
 
1.1.2. Metastasis as a multistep, evolutionary process. 
Metastatic outgrowth and generation of clinically detectable metastases is a final product of a 
series of events collectively termed invasion metastasis cascade [9]. During the course of this 
process cancer cells of the primary tumor need to pass through various steps, all of which 
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pose a selective pressure for cancer cells: (1) invade locally through extracellular matrix and 
stromal tissue, (2) enter the hematogenous or lymphatic circulation, (3) survive the transit 
through the vasculature, (4) arrest at the metastatic site, (5) extravasate into the parenchyma 
of the distant tissue, (6) survive in the foreign microenvironment of the distant organ, and (7) 
reinitiate proliferation [9]. Each of these impediments exerts different selective pressure on 
cancer cells necessitating them to acquire new traits to adapt to the surrounding conditions. 
Therefore, every step in the metastatic cascade can limit or terminate further spread, 
proliferation, and survival of cancer cells [9-11]. Consequently, selection of the cellular clone 
with the highest metastatic potential is likely to be based on the principles of asexual 
evolution of neoplastic cells [12]. For the succeeding cycles of selection and adaptation to 
take place, a mechanism is needed providing heterogeneity within the population of 
metastasizing cancer cells. Heterogeneity of the neoplastic cells may result from genome 
instability, a characteristic which is considered to be one of the hallmarks of cancer [13]. 
Acquisition of genetic changes results in generation of heritable phenotypes, which may 
confer selective advantage to overcome environmental barriers occurring along the metastatic 
cascade, ultimately leading to selection of full malignancy. Therefore, to effectively treat 
cancer it is critical to identify key genetic events preceding metastatic outgrowth of tumor 
cells in ectopic organs.  
 
1.1.3. Models of metastatic cancer progression. 
For a long time it was assumed that the genetic evolution of an individual cancer, from its 
ontogeny to full malignancy, takes place within the microenvironment of the primary tumor. 
This was supported by an observation that accumulation of genetic and epigenetic alterations 
was strongly associated with the stepwise acquisition of morphological abnormalities by the 
tumor tissue [14]. Based on these findings, a linear progression model of metastasis was 
established (Figure 1A) [14]. According to this paradigm, tumor progression is associated 
with gradual acquisition of advantageous genetic changes, e.g. activation of oncogenes or 
inactivation of tumor suppressor genes caused by mutations, allowing clonal expansion of 
more aggressive cellular variants producing larger and more dysplastic tumors. In this 
process, the ability of cancer cells to metastasize is strongly associated with the accumulation 
of genetic and epigenetic changes [14]. Therefore, the capacity to metastasize was largely 
restricted to cancer cells of large, late-stage tumors only, which already acquired full 
malignancy. Consequently, the genetic landscape of cancer cells present in the circulation 
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(both lymphogenous and hematogenous) and the matched primary tumor should be similar. 
Should this model be true, then the primary tumors could be used as good surrogate markers 
for selection of therapies, as it would comprise the complete set of genetic event that have led 
to the development of metastases. Although the linear progression model of cancer has been 
widely accepted, several clinical observations are not fully compatible with this concept. First, 
distant metastases can develop at early stages of cancer progression from small tumor lesions. 
For instance, systemic spread of cancer cells, manifested by the presence of disseminated 
cancer cells (DCCs) in the bone marrow, could be detected in 13-21% of patients with ductal 
carcinoma in situ (a premalignant lesion of mammary epithelium) [15-17] and in 29% of 
breast cancer patients with T1 stage tumors (tumor size < 2cm) [18]. Second, 5-10% of cancer 
patients are diagnosed with so called cancer of unknown primary origin, wherein metastatic 
disease was detected even though the location of the primary lesion could not be determined 
[19]. Third, seemingly non-metastatic early-stage cancer may relapse even after a complete 
resection of the primary tumor [20,21]. Due to these contradictions, a second model of tumor 
progression was established, termed “parallel progression model” (Figure 1B) [22]. 
According to this model, cancer cells leave the primary tumor early and simultaneously 
disseminate to various distant sites, where they progress in parallel with the primary lesion 
and acquire various traits, while adapting to the local microenvironment. Apart from the 
clinical observations stated above, this model was further supported by experimental data 
from studies on murine models of breast cancer. In the study published by Hüsemann and 
colleagues it was shown that systemic spread of cancer cells can be detected at the 
premalignant stage of tumor progression [17]. In addition, results of another study, by 
Podsypanina et al. showed that phenotypically normal, untransformed, mammary epithelial 
cells may survive in the circulation and, after oncogene activation has occurred, form 
metastases in distant organs [23]. Given that systemic spread of cancer cells is early, the 
course of tumor progression at the ectopic sites and in the primary tumor may vary 
substantially leading to development of distinct cancer genotypes and phenotypes. If this 
would be the case, then the genetic information confined in the primary tumor alone would 
have to be deemed insufficient to accurately identify patient subsets that could benefit from 
targeted anti-cancer therapies necessitating concurrent analysis of cancer cells present in the 
circulation.  
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Figure 1. 
 
Models of systemic cancer progression. 
In the linear progression model (A) genetic clones of cancer cells (here depicted symbolically as circles; various 
colors represent unique genetic subclones) accumulate oncogenic changes gradually becoming increasingly 
malignant. The ability to metastasize is restricted to cells that have acquired full malignant potential. 
Consequently metastatic spread is a late event in the systemic progression and the level of genetic diversity 
between primary tumor and metastasis will remain low. In contrast in parallel progression model (B) 
dissemination starts early – before cancer cells attained a fully malignant potential. Consequently, further steps 
of cancer progression take place in parallel at multiple anatomical sites (both in primary tumor or distant sites) 
generating heterogenic cancer clones. Figure adapted from Caldas C. [24] and Greaves M. et al [25]. 
 
1.2. Detection and analysis of metastatic cancer spread. 
1.2.1. Overview of methods for detection of minimal residual disease. 
Multiple assays were developed to identify and enumerate DCCs in lymph nodes or bone 
marrow and circulating tumor cells (CTCs) in the blood [26-28]. However, due to the 
extremely low tumor burden in the circulation of cancer patients (approximately 1 tumor cell 
in 10
5
 to 10
7
 of nucleated blood or bone marrow cells [29]), which is well beyond the 
detection limit of standard histopathological analysis, direct detection and isolation of tumor 
cells is not practical without prior enrichment. This is achieved by means of density 
centrifugation, selection based on physical properties (such as cell size) or expression of 
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tumor associated markers (Table 1) [30-40]. A variety of methods have been used for the 
subsequent identification of DCCs or CTCs [41-43]. Detection of tumor cells is based on 
methods capable of distinguishing cells of different origin, i.e. hematopoietic white blood 
cells from epithelial tumor cells. Among those, the most widely used protocols are: (i) 
immunological assays or (ii) molecular methods based on polymerase chain reaction (PCR) 
(Table 2). Immunological assays utilize monoclonal antibodies to select cells based on the 
expression of various proteins, e.g. epithelial markers such as epithelial cell adhesion 
molecule (EpCAM) or cytokeratins (CKs) (used for positive selection) and/or common 
leukocyte antigen CD45 (used for negative selection) [26,27,44].  
 
Table 1. Methods for enrichment of DCCs and CTCs. 
Basis  
of selection 
Selection criteria Method Technologies/Media 
Physical 
properties 
Buoyant density Density Centrifugation 
Percoll [45] 
Ficoll-Isopaque [20,21,32,45-48] 
OncoQuick [32] 
Leukapheresis [49] 
Cell size Microfiltration 
Isolation by Size of Epithelial Tumor Cells 
(ISET) [38] 
Micro-Electro-Mechanical System 
(MEMS)  [39] 
ScreenCell [50] 
Biological 
properties 
Expression of 
marker proteins 
Immunomagnetic cell 
enrichment 
CellSearch [33] 
AdnaTest [51] 
MagSweeper [34] 
Magnetic Activated Cell Sorting (MACS) * 
Immunofluorescence-based 
enrichment 
Fluoresce Activated Cell Sorting (FACS) * 
Fiber-optic array scanning technology 
(FAST) [52] 
Other immunoassays  
(based on affinity to 
antibody coated surface) 
CTC Chip [53] 
EPISPOT [54] 
Nanodetector [55] 
* - multiple reagents and systems customizable to various marker proteins. 
 
Molecular approaches on the other hand, target known genetic alterations of the DNA 
sequence (e.g. mutations of KRAS or TP53 gene [56,57]) or aberrant expression of tissue 
specific or tumor associated markers [26,27,29,58,59]. Both detection systems provide 
clinically relevant information on the prognosis of cancer patients. However, the advantage of 
the immunological assays is that they allow morphological identification and subsequent 
isolation of tumor cells for further analyses, thereby allowing more comprehensive studies of 
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DCCs and CTCs, in particular enabling analysis of cellular heterogeneity and clonal 
composition of these cell populations. Due to this limitation of the molecular detection 
methods, the remaining part of this chapter will be focused exclusively on the 
immunocytochemical detection of occult metastatic cells.  
  
Table 2. Methods for detection of DCCs and CTCs. 
Detection principle Methods Tumor entities Marker 
Immunocytochemical 
approaches 
Immunostaining 
Breast cancer 
Cytokeratins[18,60], HER2[61], 
MUC1[62] 
Colon cancer Cytokeratins[31,63] 
Esophageal 
cancer 
Cytokeratins[64], EpCAM[65] 
Gastric cancer Cytokeratins[66] 
Lung (NSCLC) Cytokeratins[67], EpCAM[68] 
Prostate cancer Cytokeratins[69,70] 
Melanoma HMB45[71], MCSP[72] 
Breast cancer, 
colon cancer, 
prostate cancer 
CD45[60,63,69] 
(negative selection) 
Molecular approaches 
RT-PCR 
Breast cancer 
CEA[73], KRT19[74], SCGB2A2[75], 
EpCAM/MUC1/HER2*[76], 
KRT19/SCGB2A2*[77] 
Colon cancer CEA[78,79], KRT20/CEA*[80] 
Lung (NSCLC) KRT19/UCKL1/FN1/TRIM28*[81] 
Pancreatic cancer KRT20[82] 
Prostate cancer PSA[83] 
Membrane-array Gastric cancer KRT19/CEA/hTERT/MUC1*[84] 
Mutation analysis 
Pancreatic cancer KRAS[57] 
Colon cancer KRAS[56] 
* - panels of markers used for detection. 
 
1.2.2. Overview and clinical application of immunological assays for detection 
of occult micrometastatic tumor cells. 
In the late 1980s and early 1990s several immunocytochemistry assays were designed 
employing monoclonal antibodies to detect occult micrometastatic cells based on the 
expression of various epithelial markers, including CKs (component of epithelial 
cytoskeleton), mucin (membrane-bound protein forming protective mucous barriers on 
epithelial surfaces), prostate specific antigen (PSA) and EpCAM (also known as 17-1A or 
HEA125) [85,86]. However, the detection rates of these approaches varied considerably 
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depending on the tumor type, tumor stage and the monoclonal antibody used [87,88]. For this 
reason, attempts have been made to standardize the immunocytochemistry protocols for 
detection of DCCs [44]. As a result guidelines have been established for detection of DCCs in 
the bone marrow of breast cancer patients recommending detection of cancer cells by pan-
cytokeratin antibodies directed against a wide spectrum of CKs (i.e. antibody A45-B/B3 
directed against a common epitope of CKs 8, 18 and 19) [44]. In a similar study, EpCAM was 
shown to be the most reliable marker for detection of DCCs in the lymph nodes of carcinoma 
patients [89]. Detection of cytokeratin positive cells in bone marrow or EpCAM positive cells 
in lymph nodes of non-metastatic cancer patients was strongly associated with an inferior 
outcome of breast, prostate, lung and esophageal cancer patients indicating that cells detected 
by both assays are truly cancer cells [18,64,70,90-92]. In a more recent study, similar 
association was also found between the survival time of breast cancer patients and the 
presence of occult cytokeratin positive (CK+) cancer cells in the peripheral blood. Strikingly, 
detection of CK+ cells was prognostically relevant only for metastatic but not for early stage 
cancer patients [93]. Nevertheless, since the peripheral blood is easy to obtain and its biopsy 
is less invasive than the aspiration of bone marrow, a series of techniques have been 
developed to specifically detect CTCs [26,28,59]. The most relevant approach in this context 
is the CellSearch
®
 System, a device allowing semi-automated positive immunomagnetic 
enrichment (using EpCAM specific antibodies) and subsequent enumeration of CKs
(+)
/ 
CD45
(-)
/nucleated (DAPI
(+)
) cancer cells [33]. In prospective clinical studies positive 
detection of CTCs by the CellSearch
®
 system (defined as ≥ 5 or 3 CTCs in 7.5 mL of blood) 
showed a significant association with overall and progression-free survival time of patients 
with metastatic breast, prostate and colon cancer [60,63,69]. These findings led to the 
clearance of the approach by the U.S. Food and Drug Administration  (FDA) for the detection 
of CTCs in the peripheral blood of patients with afore the mentioned malignancies. More 
recent reports showed that CTCs detected by the CellSearch
®
 System of non-metastatic 
cancer patients allowed prediction of early recurrence and decreased overall survival in breast 
cancer patients. This, however, was only possible when using larger sample volumes (i.e. 
mononucleated cell fraction extracted from the whole circulating blood by means of 
diagnostic leukapheresis) and/or reduction of the detection thresholds to only one CTC per 
specimen, thereby reducing the feasibility of these approach [49,94-96]. Therefore, at least for 
early stage cancer patients, detection and enumeration of occult micrometastatic cells is more 
reliable if using manual immunologic detection methods mentioned before.  
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1.2.3. The need for more detailed analysis of mircometastatic cancer cells. 
Presence of occult micrometastatic lesions in the circulation of carcinoma patients allows to 
discriminate between individuals with poor and favorable prognosis. In the future this 
approach may become a valuable tool for therapeutic decision making and monitoring of the 
effectiveness of administered therapies. However, to better understand the biology underlying 
the early stages of systemic cancer spread it is necessary to comprehensively analyze detected 
metastatic cancer cells and identify the genetic programs governing this stages of disease [97]. 
Due to extremely low abundance of detectable CTCs and DCCs as well as their genetic 
heterogeneity, the true extent of genetic alterations in these cell populations can be assessed 
only at the single-cell level.  
 
1.3. Genomic analysis of single cells. 
1.3.1. Overview of the methods available for the analysis of single cell genomes. 
Application of single-cell analysis allows to analyze minimal amounts of DNA material and 
reveals the biological complexity of cell populations, which would be obscured by analyzing 
bulk DNA. However, owing to the limited amount of genomic DNA in a single cell 
(approximately 6.5 pg) [98] direct analysis of single-cell DNA is challenging and the number 
as well as the type of downstream assays becomes significantly diminished allowing 
simultaneous analysis of a maximum of 96 loci by assays based on PCR or 12 loci by 
methods based on fluorescent in situ hybridization (FISH) [99,100]. Single-cell PCR was first 
used in the clinic in preimplantation genetic diagnosis (PGD) of monogenic diseases, such as 
cystic fibrosis, sickle cell anemia or β-thalassemia [101-103], sex determination of embryos at 
risk of X-linked diseases and, more recently, for the quantitative aneuploidy screening [99]. 
Single-cell PCR approaches were partially replaced by FISH, as it allowed detection of 
chromosomal mosaicism within the embryo and screening for translocations [104,105]. 
However, both methods (PCR and FISH) have several inherent shortcomings, in particular 
suboptimal reliability and accuracy, as well as limited amount of loci that can be 
simultaneously tested [106-108]. Hence, over the last twenty five years substantial efforts 
have been invested to develop and improve methods allowing amplification of the entire 
human genome [47,109-118]. These approaches, collectively termed whole genome 
amplification (WGA), were design to provide a comprehensive, accurate and unbiased 
representation of the starting material in amounts sufficient for extensive downstream testing. 
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Currently existing WGA approaches are based on multiple displacement amplification 
(MDA) [113-115], variants of polymerase chain reaction (PCR) [47,109-112,116] or a 
combination of both of these technologies (Table 3) [117,118]. However, none of these 
technologies is without drawbacks and, due to inherent characteristics of their design, all 
WGA methods are prone to introduce different types of bias, which may influence the 
evaluation of downstream analyses.  
The WGA-related amplification bias may include the following: 
(i) Quantitative amplification bias causing considerable representation bias of 
individual loci and random losses of alleles (allelic drop-out; ADO) [113,119-
121].  
(ii) Qualitative amplification bias caused by formation of amplification artefacts such 
as chimeric sequences linking non-contiguous loci in the DNA [115,120,122].  
(iii) Incomplete coverage of the amplified genomes leading to underrepresentation of 
template DNA [115,120,123]. 
(iv) Poor performance with partially degraded template DNA [114,124-127]. 
(v) Stochastic priming of template DNA molecules, which may hamper the 
downstream analysis of WGA products [115,126]. 
 
Table 3. Overview of WGA technologies. 
WGA Technology 
DOP-PCR  
[109] 
PEP-PCR  
[111] 
OmniPlex/ 
GenomePlex  
[116,128]  
SCOMP/  
Ampli1 WGA 
[47] 
RepliG/ 
GenomiPhi  
[129,130] 
PicoPlex™/ 
SurePlex™/  
EasyAmp™[117] 
MALBAC 
[118] 
Mechanism PCR PCR PCR PCR MDA MDA+PCR MDA+PCR 
Primer design HybridA Random Defined Defined Random HybridA HybridA 
Priming pattern Random Random Random Defined Random Random Random 
Applicability to 
genome-wide 
analysis of single-
cell genomes 
mCGH 
[131-134] 
aCGH(B) 
[135] 
Not 
applicable 
aCGH 
[136-141] NGS 
[138,142,143] 
mCGH 
 [20,21,45-48,71,72], 
aCGH 
[71,144-146] 
NGS 
[147] 
mCGH 
[113,148] 
aCGH 
[141,149-153] 
NGS 
[118,120,138,154] 
aCGH 
[155,156] 
 NGS 
[120] 
NGS 
[118] 
Single-cell genome 
coverage 
Not 
assessed 
Not assessed up to 38,7%[143] up to 74%[147] up to 72%[118] < 36%[120] 
up to 93% 
[118,157-159] 
Applicability to 
analysis of single 
DCCs or CTCs 
Not 
assessed 
Not assessed 
Yes 
[137-139,143] 
Yes 
[20,21,45-
48,71,72,144,145] 
Yes 
[138] Not assessed 
Yes 
[159] 
A – primer contain random and defined sequence 
B – poor performance in aCGH 
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Inherent characteristics of the different WGA approaches make them better suited for specific 
types of samples, e.g. formalin fixed paraffin embedded (FFPE) tumor tissue specimens 
[114,125,127], or specific downstream applications [120,141]. For instance, approaches using 
random primer design, e.g. DOP-PCR, PEP-PCR and MDA are considered to be suboptimal 
for analysis of partially degraded DNA samples [114,124-127] and PCR-based approaches 
were shown to be more accurate for the assessment of copy number changes in single-cell 
WGA products [120,141]. Therefore, WGA methods should be carefully selected depending 
on the type of analysis to be conducted and the type of samples under investigation. Due to 
their high reliability of processing samples with compromised DNA quality [125-127] WGA 
methods based on adaptor mediated PCR, in particular GenomPlex and SCOMP, were used in 
most studies on CTCs and DCCs [8,20,21,45,46,48,71,137-140,143-146,160]. Genomic 
profiling of these samples is especially challenging due to fixation of cells performed prior to 
the amplification of DNA. Therefore, WGA approaches used to process DCCs and CTCs 
need to be highly robust and show high tolerance to the adverse effects of fixation [144]. 
 
1.3.2. Comprehensive analysis of single cell genomes. 
With the advent of WGA technologies more comprehensive analysis of single-cell genomes 
became possible. Combination of WGA approaches with metaphase comparative genomic 
hybridization (mCGH) allowed genome-wide screening for copy number alterations in single 
cells [47,131,134]. mCGH utilizes two samples, test (putatively aberrant) and reference 
(harboring no copy number changes), which after differential labeling are hybridized to 
metaphase spreads (Figure 2). This approach proved to be very useful for both PGD and 
analysis of single DCCs allowing to screen the whole complement of chromosomes for the 
presence of copy number changes [17,20,21,45,47,132,161-164]. However, due to limited 
resolution (10-20 Mb), high labor intensity and lack of high-throughput capabilities of mCGH 
it was soon replaced by array-based CGH (aCGH) approaches (Figure 2). Standard DNA 
microarrays constructed of BAC clone libraries allowed detection of submicroscopic copy 
number alterations as small as 2.8 Mb in single trophectoderm cells and 8.3 Mb in unfixed 
tumor cells [136,155]. Later, utilization of an improved BAC clone based aCGH platform 
allowed detection of copy number alterations of 1-2 Mb in unfixed cells and 4.4 Mb in DCCs 
[145].  
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Figure 2.  
 
Principle of CGH. 
In an CGH experiment test and reference DNA are differentially labeled with two fluorescent dyes (e.g. Cy5 or Cy3, 
respectively) and co-hybridized on an array of defined DNA probes (array CGH – aCGH) or metaphase spreads (metaphase 
CGH – mCGH). Following hybridization, florescent ratios (Cy5/Cy3) are quantified revealing copy number variations 
between test and reference samples. Genomic gains and losses are recognized as fluorescent ratios higher or lower than one, 
respectively. The accuracy of mCGH is limited by the observable banding resolution of metaphase chromosomes to a level of 
approximately 450 cytobands (5-10 Mb). In contrast, in array aCGH up to several millions of loci (represented by defined 
DNA probes) can be quantified simultaneously resulting in higher resolution of the method. 
 
Further improvements were achieved by the introduction of modern oligonucleotide aCGH 
platforms. Denser distribution of probes in the pre-selected regions of interest allowed 
detection of 1 Mb-sized genomic alteration in unfixed lymphoblastoid cell and 2.6-3.0 Mb in 
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DCCs [137,156]. However, Möhlendick and coworkers have shown that copy number 
changes as small as a remarkable 56 kb in size can be detected in unfixed single cells without 
the need to use targeted array designs [146]. This, however, was only possible when using 
SCOMP WGA technology [146]. Collectively, studies using single-cell aCGH provided 
conceptual evidence that cost-effective, high resolution screening for copy number changes in 
genomes of single CTCs and DCCs is feasible with the use of modern DNA microarray 
platforms. However, attention needs to be paid to the experimental design and selection of 
analytical tools. With the advent of next generation sequencing (NGS) technologies, several 
groups attempted to analyse single-cell genomes with higher resolution. The efficacy of 
single-cell NGS was first shown by Navin et al., who applied low resolution sequencing to 
single nuclei of fresh frozen tumor cells allowing to study the genetic structure of cancer cell 
population in tumor tissue [142]. Subsequently, other groups utilized whole genome or whole 
exome sequencing approaches on single cells, allowing to study the rate of aneuploidy and de 
novo mutations in human gametes and unfixed cancer cells [118,165,166]. More recently, 
whole genome and whole exome NGS approaches were also applied to DCCs and CTCs 
enabling to capture copy number changes or mutation profiles of single cancer cells 
[138,143,159]. However, given the high cost for sequencing of a single-cell genome and high 
complexity of the subsequent computational analysis, NGS technologies are not feasible for 
routine use for screening of large patient collectives. Therefore, if the aim of the analysis is 
focused on the high-throughput analysis of copy number alterations in single cells, it still 
seems to be more rational to use more cost effective methods based on DNA arrays. 
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1.4. Aim of dissertation. 
The aim of this thesis was to develop a reliable method for comprehensive, high-resolution 
copy number analysis of single-cell genomes after whole genome amplification (WGA). At 
the start of the project, single-cell metaphase CGH (mCGH) or BAC-based array CGH 
(aCGH) allowed detection of chromosomal imbalances with resolution of 10-20 or 1-2 Mb, 
respectively, concealing smaller (< 1Mb) aberrations and limiting the accuracy of breakpoint 
detection. To overcome these limitations, a novel high-resolution aCGH workflow had to be 
developed allowing more precise mapping of copy number variations in single-cell genomes.  
To maximize the reliability and the generality of use, the new method should allow the 
following: (1) applicability to amplified DNA samples, in particular single-cell WGA 
products, (2) qualitatively and quantitatively faithful genome-wide assessment of 
chromosomal imbalances, (3) high sensitivity enabling detection of copy number aberrations 
with a resolution of <1Mb, (4) high specificity minimizing the rates of false-positive detection 
of chromosomal imbalances, (5) robustness to process clinical samples with decreased DNA 
quality such as immunostained DCCs or tumor FFPE tissue specimens, (6) uncomplicated 
experimental and analytical procedures allowing rapid processing and analysis of samples.
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2. Materials and methods. 
2.1. Materials. 
2.1.1. Reagents.
# Description Manufacturer 
1. 1 kb DNA Ladder  Invitrogen 
2. 1× TE (pH 8.0), Molecular grade Promega 
3. 2-Log DNA Ladder (0.1-10.0 kb) New England Biolabs 
4. 4',6-Diamidine-2'-Phenylindole Dihydrochloride (DAPI), 10 mg Roche Diagnostics 
5. AB-Serum (human) Biotest AG 
6. Acetonitrile Merck 
7. Adenosine-5'-Triphosphate (ATP)-Lithiumsalt Solution, 100 mM Roche Diagnostics 
8. Agarose Sigma Aldrich 
9. Anti-Digoxigenin-FITC, Fab Roche 
10. Anti-Digoxigenin-Fluorescein, Fab Fragments Roche Diagnostics 
11. APAAP- Komplex Dako 
12. Avidin Cy3.5, Purified Biomol 
13. Avidin-Cy3.5 USBIO 
14. Barrycidal PAN Biotech 
15. BCIP/NBT (AP Color Reagent) Bio-Rad 
16. BerEP4 Mouse, Monoclonal, M0804, 250 µg/mL Dako 
17. Biotin-16-dUTP, 1 mM Roche 
18. Boric Acid Sigma Aldrich 
19. Bovine Serum Albumin (BSA), 20mg/ml Roche Diagnostics 
20. Bovine Serum Albumin (BSA), Factor V Sigma Aldrich 
21. CEP 17 FISH Probe, 17q11.1-11-1, Alpha Satellite SpectrumGreen Abbott Molecular 
22. Chloric Acid (HCl), 37% (12M) J.T. Baker 
23. Cot-1 DNA, 1.0 mg/mL Roche Diagnostics 
24. Cot-1 DNA, 1.0 mg/mL Invitrogen 
25. Cy3-dCTP (25 nM) GE Healthcare 
26. Cy3-dUTP (25 nM) GE Healthcare 
27. Cy5-dCTP (25 nM) GE Healthcare 
28. Cy5-dUTP (25 nM) GE Healthcare 
29. Digoxigenin-11-dUTP, 1 mM Perkin Elmer 
30. Disodium Phosphate (Na2HPO4) Sigma Aldrich 
31. DMEM/F12 Without L-Glutamate PAN Biotech 
32. dNTP Set (100 mM Each dATP,dCTP,dGTP,dTTP) GE Healthcare 
33. Dulbecco’s PBS + MgCl2 And CaCl2 Sigma Aldrich 
34. Eosin Sigma 
35. Ethanol Abs. J.T. Baker 
36. Ethidium Bromide, 1% Fluka 
37. Ethylenediaminetetraacetic Acid (EDTA) Sigma Aldrich 
38. Expand Long Template PCR System Buffer 1 Roche Diagnostics 
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39. FCS/FBS PAN Biotech 
40. Ficoll Paque Plus GE Healthcare 
41. Formamide Merck 
42. Formamide Sigma Aldrich 
43. GelPilot DNA Loading Gel, 5x Qiagen 
44. Hanks’ Balanced Salt Solution (HBSS) With Phenol Red Biochrom AG 
45. Hanks’ Balanced Salt Solution (HBSS) Without  Ca2+, Mg2+, 
Without Phenol Red, 0.35 g/L NaHCO3 
Biochrom AG 
46. Hematoxilin (Mayer's) Sigma 
47. Heparin Sigma Aldrich 
48. HER-2/neu FISH Probe, 17q11.2-q12 LSI, SpectrumOrange Abbott Molecular 
49. Herring Sperm DNA, 10 mg/mL Invitrogen 
50. Igepal CA-360 Sigma Aldrich 
51. KaryoMAX® Colcemid™ Solution Sigma Aldrich 
52. L-Glutamate (L-Glu), 200 µM PAA 
53. Low Molecular Weight DNA Ladder New England Biolabs 
54. Magnesium Acetat Solution Bio Ultra,  ~1M in H2O Sigma Aldrich 
55. Magnesium Chloride Sigma Aldrich 
56. Methanol (CH3OH) Merck 
57. Monopotassium Phosphate (KH2PO4) Merck 
58. MOPC21-Isotypkontroll-Antibody (M5284), 1 mg/mL Sigma Aldrich 
59. Mouse Monoclonal Antibody A45-B/B3, 0.2 mg/mL Micromet             
(AS Diagnostics) 
60. Mouse Monoclonal Anti-Cytokeratin 18 Antibody, Clone CK2 Roche 
61. Natrium Acetate Solution, 3M (pH = 5.2) Calbiochem 
62. Natrium Chloride (NaCl) AppliChem 
63. N-Lauroylsarcosine  Sigma Aldrich 
64. Oligo aCGH/ChIP-on-chip Wash Buffer 1 Agilent 
65. Oligo aCGH/ChIP-on-chip Wash Buffer 2 Agilent 
66. OnePhorAll (OPA) Buffer, 10X Amersham 
67. Pepsin, 1 g Roche 
68. Pepton GE Healthcare 
69. Percoll GE Healthcare 
70. Polyethylene Membrane P.A.L.M. Microlaser 
Technologies 
71. Potassium acetat solution BioUltra, 5M in H2O Sigma Aldrich 
72. Potassium chloride (KCl) Sigma Aldrich 
73. Proteinase K recombinant, PCR grade solution Roche Diagnostics 
74. Proteinase K, rec. PCR grade Solution Roche Diagnostics 
75. RPMI Medium without L-Glutamate PAN Biotech 
76. Sephadex G50 Sigma Aldrich 
77. Sodium Hydroxide (NaOH) Sigma Aldrich 
78. Sodium Pyruvate Sigma 
79. Stabilization And Drying Solution Agilent 
80. Thermosequenase Buffer GE Healthcare 
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81. Tris(Hydroxymethyl)-Aminomethan (Tris) AppliChem 
82. Trisodium citrate AppliChem 
83. Tru1I, HC - 50u/µL) Fermentas 
84. Trypan Blue VWR International 
85. TWEEN® 20 Sigma Aldrich 
86. TWEEN® 20, For Molecular Biology, Viscous Liquid Sigma Aldrich 
87. Vectashield Vector Laboratories 
88. Water HPLC Grade Merck 
89. Xylol  Carl Roth 
90. Penicillin, 10.000 U/mL + Streptomycin, 10 µg/mL (Pen/Strep), 
100x 
PAN Biotech 
   
 
2.1.2. Enzymes. 
# Description Manufacturer 
1. DNA T4 Ligase, 5U/µL Roche 
2. DNA Taq Polymerase PanScript, 5U/µL PAN Biotech 
3. DNA Taq Polymerase, 5 U/µL Roche 
4. Expand Long Template PCR System PolMix Roche Diagnostics 
5. MseI Restriction Endonuclease Recombinant, 50 U/µL New England Biolabs 
6. Ribonuclease A (100 mg/ml) Qiagen 
7. Thermosequenase, 32 U/μl GE Healthcare 
8. TruI, 50 U/µL Fermentas 
9. Trypsin (10x)  PAN Biotech 
 
2.1.3. Kits. 
# Description Manufacturer 
1. Ampli1™ WGA Kit Silicon Biosystems 
2. DNeasy Blood & Tissue Kit Qiagen 
3. Oligo aCGH/ChIP-on-chip Hybridization Kit Agilent 
4. PathVysion HER-2 DNA Probe Kit Abbott Molecular 
5. SureTag Complete DNA Labeling Kit Agilent 
6. Light Cycler
®
 SYBRGreenI- Faststart-DNA-Master Mix Roche 
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2.1.4. Consumables. 
# Description Manufacturer 
1. 250 mL capacity slide-staining dish   
2. 96 Well PCR Adhesive Foil ABGene 
3. 96 Well PCR Plate ABGene 
4. Acu-Jet® Pro Pipette Controller Brand GmbH + Co KG 
5. Adhesion Slides - 2 Chambers Carl Roth 
6. Adhesion Slides - 3 Chambers Carl Roth 
7. Amicon® Ultra-0.5 Centrifugal Filter Devices; 100kDa Milipore 
8. Amicon® Ultra-0.5 Centrifugal Filter Devices; 30kDa Milipore 
9. Centrifugation Tubes (Sterile): 15 mL, 50 mL Greiner Bio-One 
10. Combitips® Plus, Repetitive Positive Displacement Dispenser/ 
Pipette Tip 
Eppendorf 
11. Cover Glass For The Hemocytometer Schubert & Weiss 
OMNILAB 
12. Cryogenic Tubes Nalgene 
13. Dextran Sulfate (Mw > 500000 g/M) Sigma Aldrich 
14. EASYstrainer™ Cell Sieve  40 µM Greiner Bio One 
15. EASYstrainer™ Cell Sieve  70 µM Greiner Bio One 
16. Epoxy Coated Slides Corning 
17. Eppendorf Repeater® Stream Electronic Pipette Eppendorf 
18. Eppendorf® Research® Pro Electronic Pipette, 8-Channel,  
0.5–10 µL 
Eppendorf 
19. Eppendorf® Research® Pro Electronic pipette, 8-Channel,  
20–300 µL 
Eppendorf 
20. Erlenmeyer Flask VWR International 
21. Filter 0.22 µM Millipore 
22. Filter Tips For Micropipette 0.1-10 µL Eppendorf 
23. Filter Tips For Micropipette 10 µL, 200 µL, 1000 µL Biozym 
24. Fixogum (Rubber Vement) Marabu 
25. Forceps Agilent 
26. Glass Bottle 100 mL, 500mL, 1000 mL, 2000mL, 5000 mL Schott 
27. Glass Micro-Hematocrit Capillaries Brand GmbH + Co KG 
28. Hellendahl Cuvette Carl Roth 
29. Hybridization Chamber, Stainless Agilent 
30. LifterSlip (70 µL Volume) Implen 
31. LightCycler® 480 Multiwell Plate 96 With PCR Adhesive Foil Roche 
32. Magnetic Stir Bar VWR International 
33. Measuring Cylinder, Glass Duran Group 
34. Measuring Cylinder, Plastic VWR International 
35. Microarray Gasket Slide 4-plex format Agilent 
36. Microtubes 0.2 mL Thermo Scientific 
37. Microtubes Racks Brand GmbH + Co KG 
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38. Neubauer Hemocytometer Schubert & Weiss 
OMNILAB 
39. Ozone-Barrier Slide Cover Agilent 
40. Pipettes: P10, P20, P200, P1000 Gilson 
41. Polypropylene Reaction tubes: 0.2 mL, 1.5 mL, 2.0 mL Eppendorf 
42. Serological Pipettes (Sterile): 5 mL, 10 mL, 25 mL Greiner Bio-One 
43. Slide Holder Agilent  
44. SurePrint G3 Human CGH Microarray Kit 4×180K  
(design code: 022060) 
Agilent 
45. Surigical Disposable Scalpels Brand GmbH + Co KG 
 
2.1.5. Laboratory Hardware. 
# Description Manufacturer 
1. Agilent G2565CA Microarray Scanner System Agilent 
2. Axioskop 40 Zeiss, Mikroscope Zeiss 
3. Benchtop Microcentrifuge Grant Bio / Kisker 
4. Centrifuge 5810 R Eppendorf 
5. DMRXA-RF8 Fluorescence Microscope Leica 
6. Electrophoresis PerfectBlue Gelsystem Peqlab Biotechnologie 
GmbH 
7. HERAsage Laminar Flow Cabinet Heraeus 
8. Hybridization Oven Agilent 
9. Hybridization Oven Rotator For Agilent Microarray Agilent 
10. Incubator Memmert 
11. Inverted Microscope OPTECH 
12. Magnetic stir plate with heating element Chemikalien und 
Laborbedarf Nierle (CLN) 
13. Medimachine DAKO 
14. Microcentrifuge, 5417 R Eppendorf 
15. Microcentrifuge, 5424 Eppendorf 
16. Microdissection Microscope P.A.L.M. Microlaser 
Technologies 
17. NanoDrop 2000c Thermo Scientific 
18. NanoDrop ND-1000 Peqlab Biotechnologie 
GmbH 
19. Orbital Shaker Schmidt 
20. PatchMan NP2 Micromanipulator Eppendorf 
21. Peltier Thermal Cycler Tetrad Bio-Rad 
22. pH Meter Sartorius AG 
23. Scale, Electronic Kern 
24. Thermal Shaker (Thermomixer Confort) Eppendorf 
25. Thermocycler qPCR, Roche LightCycler® Roche 
26. Thermocycler, FlexCycler Analytik Jena 
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27. Thermocycler, PCT-200 Thermocycler, MJ Research Bio-Rad 
28. UV-Transilluminator & CCD Camera Intas 
29. Vortex mixer VELP Scientifica 
30. Water bath Memmert 
 
2.1.6. Buffers and solutions. 
Trypsin/EDTA in 1xPBS    5 mL Trypsine (10x), 20 mL PBS (1x) 
10x Tris-Borate-EDTA (TBE) Buffer    0.9 M Tris, 0.9 M H3BO3, 20 mM EDTA  
       in H2O (deionized) 
10x Tris-Acetate-EDTA (TAE) Buffer 0.4 M Tris, 0.2 M Acetic Acid, 10 mM 
EDTA in H2O (deionized); pH = 8.0 
1x Tris-EDTA (TE) Buffer 10 mM Tris (ultrapure), 1mM EDTA             
in H2O (HPLC Grade); pH = 8.0 
10x Phosphate Buffered Saline (PBS) Buffer  85 mM Na2HPO4, 20 mM KH2PO4,  
       1.5 M NaCl in H2O (deionized) 
20x Saline-Sodium Citrate (SCC) Buffer  3M NaCl,300 mM Trisodium Citrate in H2O 
(Millipore Grade) 
4x SSC       20x SSC (see above) diluted five times  
       with H2O (deionized) 
2x SSC       20x SSC (see above) diluted ten times  
       with H2O (Millipore grade) 
1x SSC 20x SSC (see above) diluted twenty times 
with H2O (Millipore grade) 
2x SSC with 0.1% NP40    0.1% (v/v) Igepal in 2x SSC 
0.4x SSC with 0.3% NP40    0.3% (v/v) Igepal in 0.4x SSC 
4x SSC + 0.2% Tween-20    0.2 % (v/v) Tween-20 in 4x SSC; pH = 7.4 
2x SSC + 0.1 % SDS      0.1% (v/v) SDS in 2x SSC 
30% Dextran Sulfate in 4x SCC   30% (m/v) Dextran Sulfate in 4x SSC 
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100% Percoll 100 mL Percoll; 9 mL HBSS without 
NaHCO3; pH = 7.4; sterile-filtered 
10x PCR Buffer      100 mM Tris-HCl pH 8.5, 500 mM KCl, 
       10 mM MgCl2 in H2O (HPLC Grade) 
10x PCR Buffer with dNTPs 5 µL of each 100 mM dATP, dCTP, dGTP, 
dTTP and 480 µL 10x PCR Buffer 
1x Tris/EDTA (TE) Buffer    Tris-HCl (10 mM), EDTA (1mM)  
       in H2O (Millipore Grade); pH = 7.4 
7/8 dNTP Mix dATP, dCTP and dGTP (10 mM each); dTTP 
(8.75 mM) in H2O (HPLC Grade) 
9/10 dNTP Mix dATP and dGTP (10 mM each); dCTP and 
dTTP (9 mM each) in H2O (HPLC Grade) 
10x One-Phor-All (OPA) Buffer Tris-Acetate (100 mM), Magnesium Acetate 
(100 mM), Potassium Acetate (500 mM)      
in H2O (HPLC Grade); pH = 7.5 
dNTP Mix (10 mM)     dATP, dCTP, dGTP, dTTP, 10 mM each 
Blocking Solution Oligonucleotide aCGH 10X Oligo aCGH/ChIP-on-Chip Blocking 
Agent (complete content of a tube)               
in 1350 µL H2O (HPLC Grade) 
Blocking Solution BAC-array aCGH 2% (m/v) BSA in 1x SSC; pH = 7.4; sterile-
filtered 
Blocking Solution mCGH 3% (m/v) BSA (Factor V), 5% (v/v) FCS,    
in 1x PBS/0.2 % (v/v) Tween-20 
Hybridization Mix BAC-array aCGH 4% (v/v) N-Lauroylsarcosine, 50% (v/v) 
Formamide, 8% (m/v) Dextran Sulfate    
(Mw >500.000 g/M) in 2xSSC; pH =7.4 
Fixation Solution mCGH 750 mL Methanol, 250 mL Acetic Acid    
(3:1 ratio) 
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Fixation Solution BAC-array CGH 50% (v/v) Formamide, 15% (m/v) Dextran 
Sulfate (Mw > 500.000 g/M) in 2x SSC 
70% Formamide in 2x SSC    70 mL Formamide, 10 mL 20x SSC,  
       20 mL H2O (deionized) 
DAPI Counterstain Solution    10 µg/ml in 4x SSC + 0.2% Tween-20 
Antibody Solution mCGH 20 µL Anti-Digoxigening-FITC antibody, 2 
µL Avidin-Cy3.5, 180 µL 1xPBS with 0.2% 
(v/v) Tween-20  
Cell Culture Medium for OE-19    10% FCS, 2 mM L-Glutamate,         
and PT-1590 esophageal cancer cell lines  1x Pen/Strep in RPMI 1640 Medium 
Cell Culture Medium for BT474    10% FCS, 2 mM L-Glutamate,         
and SKBR3 breast cancer cell lines   1 mM sodium pyruvate, 1x Pen/Strep 
       in RPMI 1640 Medium 
Cell Culture Medium for MDA-MB-361   10% FCS, 2 mM L-Glutamate,         
and MDA-MB-453 breast cancer cell lines  1x Pen/Strep in DMEM Medium 
Ethanol solution     Dilution of absolute ethanol solution 
70% (v/v), 85% (v/v), 90% (v/v)    in H2O (Millipore or HPLC Grade) 
 
2.1.7. Patients. 
The ethics committee of the University of Regensburg (ethics vote number 07-079) approved 
screening procedures for the detection of DCCs and genomic analysis of the isolated cells. 
Additionally, as control and reference samples, single mononuclear cells were obtained from 
peripheral blood of five healthy donors. Within this group, three donors provided written 
informed consent (in compliance with ethic vote number 12-101-0038 approved by the ethics 
committee of the University of Regensburg) and two healthy donors provided verbal informed 
consent only. Since the latter samples were acquired before 2008, neither ethics vote for 
voluntary blood donation nor a written consent was required for these individuals. 
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2.1.8. Cell lines. 
Two breast cancer cell lines BT-474 and SKBR3 were obtained from the repository of the 
German Collection of Microorganisms and Cell Cultures at the Leibniz Institute DSMZ 
(Braunschweig, Germany). The remaining breast cancer cell lines, MDA-MB-453 and MDA-
MB-361, were acquired from the American Type Culture Collection (ATCC). OE-19 
esophageal cancer cell line was obtained from the European Collection of Cell Cultures 
(ECACC). PT1590 cell line was originally generated at the University Medical Center 
Hamburg-Eppendorf [92]. All cell lines have been maintained in the conditions recommended 
by the distributor. Identity of all cell lines was confirmed using a PCR-based fingerprinting. 
 
2.2. Methods. 
2.2.1. Fluorescent in situ hybridization (FISH).  
Two color interphase FISH was performed using PathVysion HER-2 DNA Probe Kit 
(PathVysion Kit) with spectrum orange conjugated Vysis LSI HER-2/neu probe targeting the 
locus of ERBB2 gene (17q11.2-12) and spectrum green conjugated Vysis centromere 
enumeration probe for chromosome 17 (CEP 17) targeting pericentromeric alpha satellite 
DNA of chromosome 17 (17p11.1-q11.1). Cytospin slides, each containing 1.0-2.0 x 10
6
,
 
were thawed at room temperature for 30 min and subsequently washed in 2xSCC for 10 
minutes at 37
o
C. Next, cellular spreads were digested with pepsin for 10 min at 37
o
C. 
Thereafter, slides were washed sequentially at room temperature for 5 minutes in 1xPBS 
temperature, 5 minutes in 1% (v/v) formaldehyde and 5 min in 1xPBS. Next, slides were 
dehydrated by washing in graded ethanol series: 2 minutes in 70% (v/v) ethanol, 2 minutes in 
80% (v/v) ethanol and 2 minutes in 100% (v/v) ethanol. After drying the slide at room 
temperature, 2.0 µL of FISH probe solution was applied on the slides. Subsequently, after a 
denaturation step for 5 min at 75
o
C, hybridization of the FISH probes was conducted  at a 
constant temperature of 39
o
C for 24 hours. Thereafter, slides were washed sequentially in 
0.4x SSC with 0.3% (v/v) NP40 at 73
o
C for 2 minutes and in 2x SCC with 0.1% (v/v) of 
NP40 for 1 minute at room temperature. Finally, slides were washed in nuclease-free water 
and counterstained with DAPI. The results were quantified using the Zeiss Axio Imager 2 
system. For each specimen a minimum of 25 cells were analysed and corresponding ERBB2 
to CEP17 ratios were calculated. 
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2.2.2. Tissue processing and immunocytochemical screening for DCCs. 
Bilateral bone marrow aspirates were taken from the anterior iliac crest of breast, prostate and 
esophageal cancer patients after written informed consent was obtained. All bone marrow 
specimens were screened for the presence of cytokeratin positive (CK+) cancer cells. In 
addition, in the case of oesophageal cancer patients, lymph nodes collected intraoperatively 
during the systematic lymphadenectomy were disaggregated and screened for EpCAM 
positive (EpCAM+) DCCs. The experimental procedures for bone marrow aspiration, lymph 
node disaggregation, immunocytochemical detection and isolation of DCCs were conducted 
according to previously published protocols  [45,46,92,167]. In brief, bone marrow samples 
from cancer patients as well as blood specimens from healthy control patients were washed 
with Hank’s solution and subsequently subjected to Ficoll-Paque density gradient 
centrifugation (density, 1.077 g per mole). Lymph node tissue was washed twice in PBS and 
subsequently disaggregated mechanically into a single-cell suspension. Mononuclear cell 
fraction from bone marrow and single-cell suspension obtained from lymph nodes were 
collected, transferred on adhesion slides (0.25x10
6
 cells per 227 mm
2
), dried overnight and 
stored at -20
o
C until further use. If available, 2x10
6
 cells (2 slides) were screened for the 
presence of DCCs. Immunocytochemical detection of DCCs from bone marrow was 
performed using either the monoclonal antibody A45-B/B3 recognizing a common epitope of 
CKs 8, 18 and 19 or the monoclonal antibody clone CK2 directed against CK 18 [18,46], 
whereas cancer cells from lymph node samples were identified utilizing BerEP4 monoclonal 
antibody against EpCAM [65]. Cells collected from peripheral blood of healthy donors were 
stained using the monoclonal antibody (clone V9, Dako) against the intermediate filament 
vimentin. In parallel to cytokeratin or EpCAM staining, another slide was stained with isotype 
matched antibody (IgG1 Kappa) specific against non-human antigen (MOPC21 clone). This 
isotype control staining was utilized as negative control. Positively stained cells were 
visualized using the alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP) 
technique, with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (BCIP/NBT) 
used as substrates for the alkaline phosphatase. Single positive cells were picked from the 
slide utilizing micromanipulator mounted on an inversed microscope. After visual 
confirmation that only a single cell was picked, the isolated cell was collected in 1 µL of 
1xPBS and subjected to WGA. 
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2.2.3. Laser microdissection. 
FFPE tissue specimens were microdissected using the PALM Laser-Microbeam system 
according to the previously described protocol [127]. Briefly, FFPE tumor tissue blocks were 
cut into sequential 5 µm thick sections using a microtome with a disposable blade. Next, two 
sequential sections were further processed; one was stained with the conventional 
hematoxylin and eosing (H&E) staining for morphological inspection of the tissue, whereas 
the other was mounted on polyethylene membrane and subjected to microdissection. The 
unstained section was deparaffinized with xylene and subsequently rehydrated in a series of 
graded ethanol solutions (100%, 85%, and 70%). Following a hematoxylin staining, tissue 
sections were dehydrated in an increasing ethanol series and subsequently dried overnight in 
the presence of a desiccant. Using the PALM system selected areas of the section were 
microdissected and catapulted into the inner side of a 0.2 mL tube cap, which had been 
previously coated with PCR oil. In a subsequent centrifugation step, 14.000g for 5 minutes, 
tissue sections were transferred to the bottom of the tube and mixed with 3 µL of the 
proteinase K digestion mix composed as outlined in Table 4. 
 
Table 4. Composition of the proteinase K digestion mix. 
No.  Reagent Volume  
1. 10x One-Phor-All-Plus Buffer * 0.2 µL 
2. Tween-20 (10% v/v) 0.13 µL 
3. Igepal (10% v/v) 0.13 µL 
4. Proteinase K (10mg/ml) 0.26 µL 
5. PCR-grade H2O 1.28 µL 
* 10x One-Phor-All-Plus Buffer (OPA): 10 mM/L Tris-acetate, pH 7.5, 10 mM/L Mg-acetate, 50 mM/L K-acetate 
 
2.2.4. Primary whole genome amplification (WGA). 
All single cells, cell pools (approximately 100-1000 single cells) and FFPE tumor tissue were 
amplified using the SCOMP WGA technology [46,47,127], which is based on ligation 
mediated PCR, wherein genomic sequence is deterministically fragmented with MseI 
endonuclease prior to ligation and amplification steps (Figure 3).  
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Figure 3. 
 
Overview of the processes underlying SCOMP WGA. 
SCOMP WGA consists of five consecutive steps: (1) cell lysis, (2) digestion of template, (3) preannealing of PCR 
adaptors, (4) ligation and (5) PCR-based amplification. Utilization of restriction endonuclease (MseI) at the second 
step of the procedure assures deterministic and reproducible pattern of DNA fragmentation and priming. Moreover, the 
use of dedicated design of oligonucleotide comprising PCR adaptors prevents their self-ligation, thereby increasing the 
efficiency of PCR.  
 
Single cells or cell pools were collected in a 1.0 µL of PBS and added to 2µL of the 
proteinase K digestion buffer (Table 4), which had been previously dispensed into 0.2 mL 
reaction tube. The digestion was conducted in a PCR cycler with heated lid at 42°C for 10 
hours in the case of single cell and cell pools or 15 hours for the FFPE tissue specimens. 
Subsequently proteinase K was heat-inactivated at 80°C for 10 min. Next, the sampled DNA 
was digested with MseI restriction endonuclease by adding 0.2 µL 10x OPA buffer, 10 U of 
MseI and water to a total volume of 5 µL. The restriction digestion was performed for 3 hours 
at 37
o
C and thereafter enzyme was heat-inactivated at 65
o
C for five minutes. Simultaneously, 
to the MseI digestion, PCR adaptors were prepared for the subsequent ligation mediated PCR. 
The PCR adaptors consisted of two oligonucleotides, either LIB1 (5′-AGT GGG ATT CCT 
GCT GTC AGT-3′) and ddMse11 (5′-TAA CTG ACA GCdd-3′) or, in the case of DCCs of 
breast cancer DCCs collected at the first analytical time point (details to be found in the result 
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section), MseLig 21 (5′-AGT GGG ATT CCG CAT GCT AGT-3′) and MseLig 12 (5′-TAA 
CTA GCA TGCdd-3′), which were mixed in equimolar concentrations (0.5 µL of 100 µM 
stock solution, each) with 0.5 µL of 10x  OPA Buffer and 1.5 µL of H2O. The annealing of 
the oligonucleotides forming the PCR adaptors occurred during an incubation step, in which 
the temperature was initially raised to 65
o
C and then decreased with a constant ramp of 
1
o
C/minute to 15
o
C. Next, 1 μL of ATP (10 mM) and 1 μL T4-DNA-Ligase (5 units) were 
added to the pre-annealed PCR adaptors, which were then ligated over night at 15
o
C with the 
genomic DNA previously processed with MseI. The resulting genomic representation was 
amplified in a subsequent PCR reaction consisting of reagents outlined in Table 5. For this 
procedure, the MJ thermocycler was programmed using the settings listed in Table 6. 
Alternatively, for samples processed with MseLig 21-MseLig 12 adaptors, PCR was 
conducted as previously specified [47]. 
 
Table 5. Composition of the primary WGA reaction. 
No.  Reagent Volume  
1. Expand-Long-Template PCR 
System Buffer 1 
3.0 µL 
2. dNTPs (10 mM, each) 2.0 µL 
3. Expand-Long-Template PCR 
System Polymerase Mix (5 U/µL) 
1.0 µL 
4. PCR-grade H2O 35 µL 
 
Table 6. PCR program used to run the primary WGA reaction.  
Step Temperature Time Repetitions 
1.  68
o
C 3:00 min 
 
2.  94
o
C 0:40 min 
15x 3.  57
o
C 0:30 min 
4.  68
o
C 1:30 min + 1 sec/cycle 
5. 94
o
C 0:40 min 
9x 6.  57
o
C + 1
o
C/cycle 0:30 min 
7.  68
o
C 1:45 min + 1 sec/cycle 
8.  94
o
C 0:40 min 
23x 9.  65
o
C 0:30 min 
10.  68
o
C 1:53 min + 1 sec/cycle 
11.  68
o
C 3:40 min 
 
12.  4
o
C for ever   
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2.2.5. Re-amplification of the WGA products. 
Re-amplification of the primary WGA product was conducted according the protocol 
described by Czyz ZT et al. [144]. The composition of the re-amplification reaction and the 
corresponding PCR-program are outlined in Table 7 and Table 8, respectively. Typically three 
reactions were run in parallel, which were pooled and used as template for DNA labeling and 
aCGH. A negative (no template) control was included in every run.  
 
Table 7. Composition of the reaction used to re-amplify primary WGA products. 
No.  Reagent Volume  
1. Expand-Long-Template PCR System 
Buffer 1 
5.0 µL 
2. LIB1 (10 µM) 5.0 µL 
3. dNTP mix (10 mM) 1.75 µL 
4. BSA 1.25 µL 
5. Expand-Long-Template PCR System 
Polymerase Mix (5 U/µL) 
0.5 µL 
6. PCR-grade H2O 35.5 µL 
7. Template (undiluted WGA product) 1.0 µL 
 
Table 8. Conditions of the PCR reaction used to re-amplify the primary WGA products. 
Step Temperature Time Repetitions 
1.  94
o
C  1:00 min 
1x 2. 60
o
C  0:30 min 
3. 65
o
C  2:00 min 
4. 94
o
C  0:30 min 
11x 5. 60
o
C  0:30 min 
6. 65
o
C  2:00 min + 20 sec/cycle 
11.  4
o
C  for ever   
 
2.2.6. Quality control of the WGA products. 
The quality of WGA products was assessed by means of PCR as previously described [145], 
with minor modifications. The tested genomic loci and corresponding PCR primers are listed 
in Table 9. PCR was composed and run according to the specifications outlined in Table 10 
and Table 11, respectively. Five-fold dilution of the WGA product was used as template for 
the PCR. Due to inherent characteristics of the WGA products generated from FFPE 
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specimens, in particular significant fragmentation of input DNA caused by the fixation and 
storage, the quality of these samples could not be assessed prior to the aCGH analysis. 
Positivity for 7-8 PCR products indicated very good quality of the WGA products, whereas 
samples with 6-7 positive reactions were classified as good. Samples positive for 5 markers or 
less were not included in further analyses. 
 
Table 9. Markers and corresponding PCR primers used to assess the quality of the WGA products. 
No. Gene/Marker Forward Primer Reverse Primer 
Annealing 
Temperature 
1. D3S1514  5'-CAGCCAGCAGAATTATGAG-3'  5'-GGCAACAGAGCAAGATGC-3' 59oC 
2. D5S2117  5'-CCAGGTGAGAACCTAGTCAG-3'  5'-ACTGAGTCCTCCAACCATGG-3' 58oC 
3. D6S1633  5'-CTCATGGAGCTTATAGCCTG-3'  5'-TGTTCCTTCTGGCTAGCATG-3' 59oC 
4. D17S1322  5'-CTAGCCTGGGCAACAAACGA-3'  5'-GCAGGAAGCAGGAATGGAAC-3' 55oC 
5. BCR  5'-CGTGGACAACTACGGAGTTG-3'  5'-TCAGCCTCAGGACTCTTGTG-3' 58oC 
6. KRT19  5'-GAAGATCCGCGACTGGTAC-3'  5'-TTCATGCTCAGCTGTGACTG-3' 58oC 
7. TP53  5'-GAAGCGTCTCATGCTGGATC-3'  5'-CAGCCCAAGCCTTGTCCTTA-3' 58oC 
8. TP53  5'-AGGACCTGATTTCCTTACTGC-3'  5'-GAGGTCCCAAGACTTAGTAC-3' 58oC 
 
Table 10. Composition of the PCR used to assess the quality of WGA products. 
No.  Reagent Volume  
1. 10x PCR buffer  
with dNTP Mix (10 mM, each) 
1.0 µL 
2. Forward primer (8 µM) 0.5 µL 
3. Reverse primer (8 µM) 0.5 µL 
4. BSA 0.25 µL 
5. Taq polymerase (5U/µL) 0.1 µL 
6. PCR-grade H2O 7.25 µL 
7. Template 1.0 µL 
 
Table 11. Conditions of the PCR used to test the quality of WGA products. 
Step Temperature Time Repetitions 
1.  94
o
C 2:00 min 
1x 2.  55/58/59
o
C * 0:30 min 
3. 72
o
C 2:00 min 
4. 94
o
C 0:15 min 
15x 5.  55/58/59
o
C * 0:30 min 
6. 72
o
C 0:20 min 
7. 94
o
C 0:15 min 
25x 8.  55/58/59
o
C * 0:30 min 
9. 72
o
C 0:30 min 
10. 72
o
C 2:00 min   
11.  4
o
C for ever   
*Annealing temperature depended on marker tested (Table 9). 
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2.2.7. Isolation of bulk genomic DNA. 
High-molecular-weight genomic DNA was isolated either from mononuclear cell fraction of 
the peripheral blood of healthy donors or cancer cell line cells collected from adherent cell 
cultures. Unamplified genomic DNA was isolated using the Qiagen DNeasy
®
 Blood & Tissue 
Kit according to the manual provided by the manufacturer (DNAeasy Blood & Tissue 
Handbook 07/2006). In brief, a maximum of 5x10
6 
cells were collected and resuspended in 
200 µL of sterile 1x PBS buffer. Next, cell suspension was supplemented with 20 µL of 
Proteinase K (concentration not indicated by the manufacturer), 4 µL of RNase A (100 
mg/ml) and 200 µL of Buffer AL, mixed thoroughly by vortexing and incubated at 56
o
C for 
10 minutes. The resulting cell lysate was mixed with 200 µL of 96% (v/v) ethanol, loaded on 
the assembled DNeasy mini spin column and spun down at 6.000g for 1 minute. After 
discarding the flow-through, the column was loaded with 500 µL of Buffer AW1 and 
centrifuged for 1 min at 6.000g. Again, the flow-through was discarded and the column was 
loaded with 500 µL of Buffer AW2. Thereafter, columns were centrifuged for 3 min at 20.000 
g, flow-through was discarded and the spin column assembly was centrifuged again (1 min at 
20.000g) to remove the residual buffers. Subsequently, DNeasy Mini Column was transferred 
to a clean microcentrifuge tube and the high-molecular-weight DNA was eluted with 2x75 µL 
of H2O. DNA was collected in a two subsequent centrifugation steps for 1 min at 6.000g. The 
quantity and the purity of isolated DNA were quantified using a NanoDrop ND-1000 
spectrophotometer. In addition, the integrity of isolated DNA was assessed on 0.8% agarose 
gel supplemented with ethidium bromide. Herefore, 300 ng of DNA was applied on a gel and 
run for 1.5 hour at 3 V/cm. 
 
2.2.8. DNA labeling and CGH hybridization on metaphase spreads (mCGH). 
Sample preparation and mCGH was performed according to a previously described protocol 
[47,168]. In brief, DNA was labeled indirectly using either digoxigenin (test) or biotin 
(reference). The PCR was composed and run according to specifications outlined in Table 12 
and Table 13, respectively. Labeled test and reference DNA were mixed and hybridized on 
the metaphase spreads in the presence of 80µg of Human Cot1-DNA, and 100µg of Herring 
Sperm DNA. The hybridization was carried out at 37
o
C for 48 hours. Subsequently, the 
metaphase spreads were washed, their images were acquired and test to reference 
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fluorescence ratios were quantified as described before [169]. The mCGH experiments 
included in this thesis were conducted as part of the dissertation of Dr. Bernhard Polzer [168].  
 
Table 12. Composition of the reaction used to label WGA products prior to mCGH.  
No.  Reagent Volume  
1. Expand-Long-Template PCR System 
Buffer 1 
4.0 µL 
2. LIB1 (10 µM) 8.0 µL 
3. 7/8 dNTP mix * 1.5 µL 
4. Digoxigenin-11-dUTP/Biotin-16-
dUTP (1.0 mM)  
1.75 µL 
5. Taq Polymerase (5 U/µL) 1.25 µL 
6. PCR-grade H2O 35.5 µL 
7. Template (undiluted WGA product) 1.0 µL 
* 7/8 dNTP mix consisted of dATP, dGTP, dCTP (10 mM, each) and dTTP (8.75 mM). 
 
Table 13. Conditions of the PCR used to label WGA products prior to mCGH. 
Step Temperature Time Repetitions 
1. 94
o
C 1:00 min 
1x 2. 60
o
C 0:30 min 
3. 72
o
C 2:00 min 
4. 94
o
C 0:30 min 
11x 5. 60
o
C 0:30 min 
6. 65
o
C 2:00 min + 20 sec/cycle 
11. 4
o
C for ever   
 
2.2.9. DNA labeling and aCGH hybridization on oligonucleotide microarrays. 
 
2.2.9.1. Random-primed DNA labeling approach (RP labeling). 
Test and reference DNA samples were labeled using SureTag DNA Labeling Kit (Agilent 
Technologies) according to the instruction provided by the supplier (Agilent Oligonucleotide 
Array-Based CGH for Genomic DNA Analysis, version 7.1, December 2011), also 
summarized by Möhlendick et al. and Czyz et al. [144,146]. Briefly, 1.5 - 2.0 µg of purified 
DNA (WGA product or unamplified genomic DNA) was mixed with 5 µL of Random Primer 
Mix and filled up with H2O to a total volume of 31 µL. Unamplified DNA and WGA product 
samples were denatured at 95
◦
C for 10 or 3 minutes, respectively. Sample tubes were 
transferred on ice and incubated for 5 min. The labeling reaction with exo-Klenow fragment 
Materials and methods 
42 
 
consisted of 31 µL of denatured DNA supplemented with random primers, 10 µL of 5x 
Reaction Buffer, 5.0 µL of 10x dNTP Mix, 3.0 µL of Cy5-dUTP (test) or Cy3-dUTP 
(reference) and 1.0 µL of Exo(-) Klenow fragment. Labeling reaction was run at 37
◦
C for two 
hours, followed by an inactivation step at 65
◦
C for 10 minutes. Labeled DNA was purified 
using Amicon Ultra 0.5 purification system with a size cut-off of 30 kDa. Herefore, the 
labeled DNA was filled up with H2O to a total volume of 480 DNA, loaded on the Amicon 
Ultra spin column assembly and centrifuged for 10 min at 14.000 g. Next, the flow-through 
was discarded, the column was loaded with 480 µL of H2O and the samples were centrifuged 
again at 14.000 g for 10 min. Subsequently, the purification column were removed and 
mounted in an upside-down position in a new collection tube. The DNA was eluted during a 
subsequent centrifugation step at 1.000 g for 1 min. Next, samples were measured with the 
NanoDrop ND-1000 spectrophotometer. The DNA yields and dye incorporation rates 
(specific activity) were quantified using Equation 1 and Equation 2, respecitvely. 
 
 
 
Equation 1. DNA Yield. 
                
                   
  
                    
    
     
 
 
 
 
 
Equation 2. Specific activity (dye incorporation rate). 
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2.2.9.2. PCR-based labeling techniques for WGA products generated by SCOMP. 
Schematic overview depicting the principles of PCR-based labeling techniques used to 
process WGA products generated by SCOMP is presented in the Figure 4. 
 
Figure 4. 
 
Schematic overview of PCR-based labeling techniques for SCOMP WGA products. 
PCR-T1 (A) utilized dye-conjugated universal primer identical to that used in SCOMP. This facilitated even 
incorporation of the dye into the amplicons of a WGA product irrespective of their size. In contrast, PCR-T2 (B) 
facilitated labeling of WGA products though incorporation of dye-conjugated nucleotides. This approach permitted 
removal of PCR-adaptor sequence prior to hybridization on the array. 
 
2.2.9.2.1. PCR-based labeling using dye-conjugated universal primer (PCR-T1).  
Conjugation of the dye directly to the universal primer provides the advantage that all 
restriction digestion fragments present in the WGA product, irrespectively of their size, will 
be labeled with the same amount of dye. To avoid cross-hybridization of adaptor sequences 
flanking amplicons in the WGA products, test and reference samples were labeled using 
different PCR-adaptors. Test samples were labeled with the PCR-adaptor used in the SCOMP 
primary WGA (paragraph 2.2.4. of this manuscript), while all the reference DNA samples 
were amplified using the following adaptors: MIB5 (5’-TGAGCTGGTCATTGCGCATGGT-
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3’) and ddMse XI (5’-TAACCATGCGC-3’). Universal primers used in the labeling reaction 
were directly conjugated with either Cy5 in the case of LIB1 primer [5’-
TAGTGGGATTCCTGCTGTCAGT-3’] or Cy3 in the cases of MIB5 primer [5’-
TGAGCTGGTCATTGCGCATGGT-3’] (underscores indicate placement of the dye). The 
labeling PCR was assembled according to the specifications outlined in Table 14. The 
labeling reaction was run in a MJ thermocycler utilizing settings listed in Table 15. Products 
were purified using the Amicon Ultra 0.5 System (cut-off size 100 kDa), utilizing the same 
protocol as in the paragraph 2.2.9.1., and quantified with the NanoDrop ND-1000 instrument 
(see paragraph 2.2.9.1.). 
 
 
Table 14. Composition of PCR-based labeling reaction using dye-conjugated primer. 
No.  Reagent Volume  
1. Expand-Long-Template PCR System 
Buffer 1 
5.0 µL 
2. Cy5-LIB1/Cy3-MIB5 (20 µM) 6.0 µL 
3. dNTP mix (10 mM) 1.75 µL 
4. BSA 0.5 µL 
5. Expand-Long-Template PCR System 
Polymerase Mix (5 U/µL) 
0.75 µL 
6. PCR-grade H2O 35.5 µL 
7. Template (undiluted WGA product) 0.5 µL 
 
Table 15. Conditions of the PCR used for labeling of WGA samples prior to oligonucleotide aCGH. 
Step Temperature Time Repetitions 
1.  94
o
C  0:15 min 
11x 2. 60
o
C  0:30 min 
3. 65
o
C  3:30 min 
4. 94
o
C  0:15 min 
3x 5. 60
o
C  0:30 min 
6. 65
o
C 
 3:30 min + 10 
sec/cycle 
7. 65
o
C  7:00 min   
8.  4
o
C  for ever   
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2.2.9.2.2. PCR-based labeling using incorporation of dye-conjugated dNTPs (PCR-T2). 
WGA products were labeled by PCR in the presence of Cy5 or Cy3 conjugated dCTP and 
dUTP. Incorporation of the fluorescent dyes using the labeled dNTPs provided the advantage 
that adaptors flanking each amplicon in the WGA product could be removed prior to the 
aCGH hybridization, thereby avoiding unspecific cross-hybridization of test sample with 
reference DNA and oligonucleotide probes on the array. For each sample, two PCR-T2 
reactions were run in parallel using the thermal profile outlined in Table 15. Each reaction 
was composed according to the recipe listed in the Table 16.   
 
Table 16.  
Composition of the PCR-based labeling reaction using incorporation of dye-conjugated dNTPs. 
No.  Reagent Volume  
1. Expand-Long-Template PCR System 
Buffer 1 
5.0 µL 
2. LIB1 (20 µM) 6.0 µL 
3. 9/10 dNTP mix (10 mM) * 1.75 µL 
4. Cy5-dCTP/Cy3-dCTP (1 mM) 1.75 µL 
5. Cy5-dUTP/Cy3-dUTP (1 mM) 1.75 µL 
6. BSA 0.5 µL 
7. Expand-Long-Template PCR System 
Polymerase Mix (5 U/µL) 
1.5 µL 
8. PCR-grade H2O 31.25 µL 
9. Template (undiluted WGA product) 0.5 µL 
* 9/10 dNTP mix comprised dATP, dGTP (10 mM each) as well as dCTP and dTTP (9 mM each) 
 
The resulting PCR products were subjected to digestion with Tru1I restriction endonuclease 
to cleave off the PCR-adaptors. For this purpose each PCR product was supplemented with 
5.6 µL of 10x Buffer R and 30 U of Tru1I. Digestion was performed at 65
◦
C for 3 hours. 
Resulting products generated for each individual WGA product were pooled and purified 
using the Amicon Ultra 0.5 System (100 kDa cut-off) using the same procedure as outlined 
before for the purification system with 30 kDA cut-off (paragraph 2.2.9.1.). DNA yields and 
dye incorporation rates were quantified using the NanoDrop ND-1000 Instrument (see 
paragraph 2.2.9.1.). 
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2.2.9.3. Array comparative genomic hybridization on oligonucleotide arrays. 
Array CGH was performed on oligonucleotide-based SurePrint G3 Human CGH 4x180K 
microarray slides (catalog design; code 022060) according the protocol provided by the 
manufacturer (Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis, 
version 7.1, December 2011). Slight modifications were introduced for WGA products 
processed with the PCR-based labeling approaches. Here, the hybridization mix consisted of 
5.0 µg of Cot1-DNA (Roche Diagnostics), 12 µL of 10x Blocking Reagent (Agilent 
Technologies), 60 µL of 2x Hi RPM Hybridization Buffer, 1% (v/v) of each Tween20 and 
Igepal, and 19 µL of each test and reference DNA. Hybridization mix was denatured at 95
o
C  
for 3 min and subsequently incubated for 30 min on a theremoblock set to 37
o
C allowing the 
Cot-1 DNA to block the repetitive DNA sequences in test and reference DNA. Next, 
corresponding test and reference samples were mixed and subjected to hybridization on 
oligonucleotide array slides. For each hybridization 100 µL of the hybridization mix was 
applied on the microarray and hybridized at 65
◦
C for 24 h. Following the hybridization the 
slides were washed twice for 2:30 min in Oligo aCGH/ChIP-on-Chip Wash Buffer 1 (Agilent 
Technologies) at room temperature and twice for 30 sec in Oligo aCGH/ChIP-on-Chip Wash 
Buffer 2 (Agilent Technologies) at 37
◦
C. Washed slides were immersed in acetonitrile to 
remove all remaining traces of the wash buffers. Finally, each slide was placed in the Agilent 
Slide Holder and scanned using an Agilent Microarray Scanner Type C using the following 
settings: Slide ID: <Auto Detect>; Channels: red and green (R + G); Scan region: 61 x 21.6 
mm; scan resolution: 3 µm double pass; Tiff: 16 bit; R photo multiplier tube (PMT): 100%; G 
PMT: 100%; XDR: <No XDR>. 
 
2.2.9.4. Processing and analysis of the aCGH data. 
Microarray TIFF image files were processed with the Agilent Genomic Feature Extraction 
Software (version 10.7) using the standard protocols for aCGH arrays (CGH_107_Sep09). 
The resulting text files were imported and analysed with Agilent Genomic Workbench 
Software (version 6.5 Lite). Saturated and non-uniform outlier features were excluded prior to 
data analysis. Aberrant regions were recognized using ADM-2 algorithm with threshold set to 
6.5 for unamplified DNA and 7.0 for WGA samples generated from immunostained cells and 
FFPE tissue specimens. Centralization algorithm was set to a threshold of 6.0 and bin size of 
10. To avoid false positive calls, aberration filters were applied to define the minimum log2 
ratio (0.25 for unamplified DNA or WGA products from freshly picked cell and 0.3 for WGA 
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product from cell subjected to immunostaining) and the minimum number of probes in an 
aberrant interval (5 for unamplified DNA, 10 for WGA products from fresh picked cells and 
30 for WGA products generated from immunostained cells, and FFPE tissue specimens). The 
microarray data presented in this manuscript has been deposited in Gene Expression Omnibus 
(GEO) database (accession number: GSE52366). 
 
2.2.9.5. Identification of minimal regions of aberration (MRAs). 
MRA refers to the smallest region of genomic copy number alteration shared across an 
analysed set of aCGH profiles (Figure 5). 
 
Figure 5. 
 
 
Detection of a minimal region of aberrations. 
Scheme depicting exemplary the process MRA detection. Blue bars indicate balanced genomic intervals, whereas 
green color indicate aberrant regions detected in the tested samples.  
 
2.2.9.6. ROC analysis and hierarchical clustering of the aCGH data. 
Accuracy of the new single-cell aCGH assay was assessed using separate ROC curves for 
gains and losses. To this end, segmentation profiles obtained by the ADM-2 algorithm were 
binarized according to threshold values (Thr): for gains, values ≥ Thr were set to unity or 0 
otherwise, for losses: values ≤ -Thr were set to unity or 0 otherwise. Reference profiles were 
binarized according to a fixed threshold of Thr = 0.25, while test profiles were binarized for 
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different values of Thr. ROC curves were obtained by comparing a reference binarization to 
test binarizations for different positive threshold values. For clustering, segmentation profiles 
were discretized according three levels, i.e. values ≥ Thr were labeled as gains by 1, values  ≤ 
-Thr were labeled as losses by -1, and all other values were labeled by zero. Hierarchical 
clustering was performed using Euclidean distance and agglomeration by complete linkage. 
Analyses were done using R [R: A Language and Environment for Statistical Computing, R 
Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2013, url = 
http://www.R-project.org]. 
 
2.2.10. DNA labeling and aCGH hybridization on BAC based microarrays. 
2.2.10.1. The design of the BAC aCGH microarrays. 
Microarrays manufactured and processed according to the previously published protocol 
[145] with minor modifications [170]. All BAC clones use to manufacture the arrays were 
obtained from BACPAC Resources at the Children’s Hospital Oakland Research Institute 
(CHORI). The design included 863 BAC clones representative for chromosome 17 and 368 
clones specific for chromosome 6. Both these BAC clone subsets originated from Human 
Genome High-Resolution BAC Re-Arrayed Clone Collection (the “32k set”) providing final 
tiling-resolution of 46 kb (url = https://bacpac.chori.org/pHumanMinSet.htm). Additionally, 
for the purpose of normalization of the aCGH data, the array design was expanded by addition 
of 192 BAC clones from the FISH Mapped Clone Collection V1.3., which is a subset of 
“Human BAC Resource Consortium_1 Set [171]. All the BAC clones were spotted on the 
epoxide coated slides with 250 µm spacing between individual spots [170]. 
 
2.2.10.2. Labeling of WGA product. 
Test and reference sample were labeled by incorporation of dNTPs directly conjugated with 
cyanine dyes during a PCR based re-amplification of the WGA products. Except for color 
switch experiments, test samples were labeled with Cy5, whereas Cy3 was incorporated into 
the reference samples. The PCR was composed and run according to specifications outlined in 
Table 17 and Table 18, respectively.  
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Table 17. 
Composition of the labeling reaction prior to hybridization on BAC aCGH microarrays. 
No.  Reagent Volume  
1. 10x ThermoSequenase Reaction Buffer 5.0 µL 
2. LIB1 (100 µM) 5.0 µL 
3. 9/10 dNTP mix (10 mM) * 2.0 µL 
4. Cy5-dCTP/Cy3-dCTP (1 mM) 2.0 µL 
5. Cy5-dUTP/Cy3-dUTP (1 mM) 2.0 µL 
6. ThermoSequenase (5U/µL) 1.0 µL 
7. PCR-grade H2O 84.0 µL 
8. Template (undiluted WGA product) 1.6 µL 
* 9/10 dNTP mix comprised dATP, dGTP (each 10 mM) as well as dCTP and dTTP (each 9 mM). 
 
Table 18. 
Conditions of the labeling reaction conducted prior to the hybridization on BAC aCGH microarrays. 
Step Temperature Time Repetitions 
1.  94
o
C  1:00 min 
10x 2. 60
o
C  0:30 min 
3. 72
o
C  5:00 min 
4.  4
o
C  for ever   
 
Products of the labeling reaction were purified on 1 mL columns filled with Sephadex-G50 
[30 g/L in 1xTE Buffer supplemented with 0.1% (v/v) SDS, pH = 8.0]. Next, corresponding 
test and reference samples were mixed with 80 μg human Cot1-DNA. Then, following 
addition of sodium acetate (final concentration 0.3 M) and 2.5 volumes of ethanol, DNA was 
precipitated over night at -20
o
C.  
 
2.2.10.3. Hybridization on BAC aCGH microarrays. 
The BAC aCGH experiments included in this thesis were conducted as part of the dissertation 
of Dr. Daniel Will [170]. 
 
2.2.10.3.1. Blocking of the microarray slides and denaturation of BAC DNA probes. 
Prior to the hybridization of DNA samples BAC microarrays were blocked with a blocking 
solution #1 composed of 2% (v/v) solution of BSA in 1x SSC buffer; pH = 7.4. Microarray 
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slides were immersed in the blocking solution #1 and incubated on an orbital shaker for 30 
min at 42
o
C with a constant stirring rate of 140 rpm. Subsequently, double stranded DNA of 
the BAC probes was denatured for 10 min at room temperature in 75 mM solution of sodium 
hydroxide. Afterwards, microarrays were washed three times for 7 minutes (room 
temperature, 140 rpm) in 2x SSC buffer. Finally, microarray slides were washed for 1 minute 
(room temperature, 140 rpm) in water and dried by centrifugation at 450g for 2 minutes at 
room temperature. Next, slides were incubated with blocking solution #2 composed of 250 µg 
of herring sperm DNA and DNA originating from six negative control WGA products 
dissolved in  80 µL of the hybridization mix [4 % (v/v) N-lauroylsarcosine, 50 % (v/v) 
formamide, 8 % (v/v) dextran sulfate in 2x SSC]. As it is assumed that minimal residual 
amounts of E.coli DNA (contaminating enzymes used in the WGA protocol) are amplified 
during the WGA, the negative control WGA products were used to block the residual E.coli 
DNA sequences present in BAC DNA probes spotted on the microarray slides. The blocking 
solution #2 was applied on the active surface of the microarray slides, which were then sealed 
with a LifterSlip™ cover slides creating hybridization chamber with 70 µL volume. 
Subsequently, slides were incubated with the blocking solution #2 for 1 hour at 42
o
C.  
 
2.2.10.3.2. Hybridization of WGA products on the BAC aCGH microarrays.  
After precipitation, labeled DNA samples (obtained in the step 2.2.14.2.) were centrifuged 
(25000g; 4 °C; 45 min) and the resulting pellets were washed in 800 µL of 70 % (v/v) 
ethanol. In parallel to the labeled test and reference DNA, six negative control WGA products 
were precipitated and isolated using the same protocol as for the labeled DNA samples. 
Following the second round of centrifugation, ethanol was removed and the DNA pellets were 
dried briefly at 42
o
C. Next, labeled DNA samples and negative WGA products were 
reresuspended in 40 µL of the Hybridization Mix BAC-array aCGH and mixed on a 
thermoblock for 1 h at 42 °C with constant stirring at 400 rpm. Subsequently, labeled DNA 
and negative control WGA products were merged, mixed and heat-denatured for 10 min at 
75
o
C. Thereafter, the samples were incubated for 45 min at 42
o
C allowing the hybridization of 
repetitive sequences in the labeled samples with Cot-1 DNA. After the blocking step was 
completed, the samples were applied on the active surface of the microarray slides, which 
were then sealed with the LifterSlip™ cover slides (with 70 µL of hybridization volume). The 
aCGH hybridization was performed for 20 hours in a SlideBooster microarray incubator with 
temperature set to 42
o
C and mix/pause intervals set to 3 s/7 s. 
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2.2.10.4. Washing of the BAC aCGH microarrays. 
Following the hybridization the BAC aCGH microarray slides were removed from the Slide 
Booster microarray incubator and LifterSlip™ 70 µL cover slides were carefully removed. 
The slides were first washed four times in 1x PBS supplemented with 0.05% (v/v) Tween-20 
(5 min, room temperature, 140 rpm) and subsequently three times in 1x SSC (5 min, 60
o
C, 
140 rpm). Following the washing, slides were dehydrated in 70% (v/v) ethanol (1 min, room 
temperature) and dried by centrifugation at 450g. 
 
2.2.10.5. Scanning of the BAC aCGH microarrays. 
The BAC aCGH microarrays were scanned using the GenePix
®
 microarray scanner 4400A 
and GenePix Pro 7 software. The device collected fluorescent signal intensities of Cy3 and 
Cy5. The PMT settings were selected automatically to assure optimal overlap over the signal 
intensities in both channels and assure a maximum of 5% of saturated features. Additionally, 
to minimize the noise of the hybridization, each location on the slide was scanned three times 
(lines to average = 3). The resulting images were saved in TIFF format. 
 
2.2.10.6. Analysis of the BAC aCGH microarrays.  
The following evaluation steps were conducted only for BAC clones representative for 
chromosome 17. TIFF files generated after scanning were first processed with GenePix Pro 7 
software. Herewith, normalized background corrected fluorescence intensity values were 
quantified. Subsequently, M- (Equation 3) and A-values (Equation 4) were calculated for each 
feature 
. 
Equation 3. Computation of the M-value. 
           
     
     
 
FICy5 – background corrected normalized fluorescence intensity of Cy5. 
FICy3 – background corrected normalized fluorescence intensity of Cy3. 
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Equation 4. Computation of the A-value. 
 
                                 
 
All features with overall low intensity (A-value < 2) were excluded from further evaluation. 
Subsequently, whenever possible, mean M-values were calculated for replicate features. 
Additionally, M-values were normalized by setting the variance of the M-value spread to 0 
and mean value to 1. The profiles were corrected for the WGA-associated bias by subtraction 
of mean Cy5/Cy3 ratio values generated across ten independent single-cell aCGH 
experiments performed using cells of healthy donors. Thereafter, mean normalized M-values 
computed for each feature were plotted against the physical position in the human genome of 
the corresponding BAC clone. The data was smoothened using the Savitzky-Golay filter.  
 
2.2.11. Single-cell quantitative PCR (qPCR) assay for detection of genomic gains 
in ERBB2 locus. 
Detection of genomic gains at the ERBB2 locus was conducted with the use of a qPCR-based 
approach (Pasch S. et al., manuscript in preparation). For each single-cell WGA product three 
amplicons in the target locus (ERBB2) and six reference loci (ATGR, CACNA, GZMB, 
RUFY2, OPN1SW and SMYD1; one amplicon for each locus) were quantified with 
LightCycler
®
 480 System using SYBR Green detection system. 100x diluted aliquots of the 
original WGA product were used as template for the qPCR. All reactions were conducted in 
duplicates and the resulting crossing point (Cp) values were computed with the LightCycler 
480 software (v 1.5.0). Samples with three or more unsuccessful measurements (crossing 
point > 30) for the reference loci or at least two unsuccessful measurements of the target locus 
were excluded from further evaluation. For each target/reference pair (18 pairs in total) 
relative locus ratio was computed (Equation 5). 
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Equation 5. Computation of calibration normalized efficiency corrected relative locus ratio. 
                      
            
        
         
        
   
            
            
                     
 
 
E – Efficiency of the PCR 
Cp – Crossing point 
 
The further steps of data evaluation were programmed and conducted in R programming 
language (R Development Core Team: R: A Language and Environment for Statistical 
Computing. Vienna, Austria, 2008). For the assessment of the data, an additive model based 
on medianpolish algorithm was used [172], which was trained with a collective of single-cell 
WGA products obtained from healthy individuals. Using this approach sample specific qPCR 
measurement was calculated for each single-cell WGA product. The mean and standard 
deviation of the qPCR values (relative locus ratios) was used to compare its distribution 
between the training cell collective and tested cells, thereby allowing to calculate the 
amplification probability for each tested cells. The amplification probability was computed 
using pnorm function implemented in R. Amplification of the ERBB2 locus were called if the 
amplification probability was greater than 0.95. 
 
2.2.12. Statistical analysis. 
The outcome of the PCR-T1 and PCR-T2 reactions (DNA yield, signal to noise ratios and 
intensity of fluorescent signals) were compared using the two-tailed unpaired Student’s t-test. 
The p-values (P) were calculated using an online t-test calculator (url = 
http://www.graphpad.com/quickcalcs/ttest1/). In each comparison, the difference between the 
values was considered as statistically significant if p-value was lower than 0.05.  
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3. Results. 
The result section is subdivided into three parts: (i) description of steps undertaken to 
establish a new single-cell aCGH protocol (3.1.), (ii) performance assessment of the new 
workflow (3.2.) and (iii) exemplary demonstration of the utility of the new method for the 
analysis of single DCCs of cancer patients (3.3.). 
 
3.1. Development of a new single-cell aCGH assay. 
3.1.1. Optimization and validation of new DNA labeling approaches customized 
for the processing of SCOMP WGA products. 
Uniform labeling of test and reference samples is crucial for the success of aCGH analysis. 
Taking into consideration the underlying principle of SCOMP, it was speculated that the most 
optimal labeling will be achieved when using a PCR-based approach. This way, all the 
amplicons comprised in a single-cell SCOMP genomic representation should be effectively 
and comprehensively labeled. To this end, two different PCR-based DNA labeling methods 
were developed, both using the same universal primer as used in the SCOMP WGA protocol. 
The first PCR-based labeling technique (PCR-T1) utilized directly conjugated oligomers as 
PCR primers, allowing incorporation of fluorescent dyes into the adaptor sequences flanking 
each amplicon in the WGA representation (Figure 4A). This allows uniform labeling of each 
amplicon, regardless of its size. The second PCR-based approach (PCR-T2) incorporated dye 
conjugated nucleotides into the WGA products (Figure 4B). This technique, although prone to 
preferentially label longer amplicons, permits removal of the PCR-adaptor sequences, whose 
presence could interfere with the subsequent aCGH hybridization. The accuracy and 
reliability of PCR-T1 and PCR-T2 were tested on PT1590 esophageal cancer cell line cells 
[92], which are known to harbour a complex pattern of copy number alterations (CNAs) 
including amplification of the ERBB2 locus on chromosome 17q21 [21,173]. Four single 
cells, three cells from PT-1590 cell line and one from a healthy female donor were isolated 
and subjected to SCOMP. Additionally, four cell pools (approximately 100-1000 cells), three 
from PT-1590 cell line and one from healthy donor, were processed with the identical 
protocols as the single cells and used as controls. The resulting WGA products were subjected 
to aCGH hybridization on Agilent SurePrint G3 Human 4x180k arrays. Fluorimetric analysis 
of the DNA labeling products revealed that PCR-T1 enabled more efficient incorporation of 
the fluorescent dyes, whereas PCR-T2 provided consistently higher DNA yields (Table 19).  
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Table 19. 
  
Cell Pool Single Cell 
PCR-T1 PCR-T2 
Student's 
t-test 
PCR-T1 PCR-T2 
Student's 
t-test 
Test DNA (cell pool/single cell) [µg] 4.1 (0.1) 13.4 (1.0) p=0.003 5.2 (0.6) 15.8 (1.1) p<0.0001 
Reference DNA (cell pool) [µg] 4.6 (0.2) 14.1 (1.6) p<0.0001 N/A N/A N/A 
Dye In corporation Test (Cy5) [ 
          
        
] 58.2 (12.9) 9.0 (2.2) p=0.0011 44.6 (3.5) 12.4 (2.1) p<0.0001 
Dye Incorporation Reference (Cy3) [ 
          
        
] 60 (5.6) 6.9 (1.5) p<0.0001 N/A N/A N/A 
Signal Intensity - Red (Cy5) [FU] 194.3 (28.6) 999.6 (150.1) p=0.0021 189.8 (118.3) 1586.1 (434.3) p=0.0025 
Signal Intensity - Green (Cy3) [FU] 42.0 (6.3) 316.2 (96.2) p<0.0001 N/A N/A N/A 
Signal-to Noise Ratio - Red (Cy5) 2.3 (1.0) 49.6 (24.1) p=0.0591 2.9 (2.3) 53.8 (10.4) p=0.0002 
Signal-to-Noise Ratio - Green (Cy3) 1.9 (0.6) 55.8 (21.8) p=0.0003 N/A N/A N/A 
 
Hybridization characteristics of samples processed with PCR-based DNA labeling techniques (PCR-T1 and PCR-T2). 
For all the variables average values and standard deviation (values in parentheses) are indicated in the table. The values 
obtained for PCR-T1 and PCR-T-2, respectively, were compared using the two-tailed Student’s t-test. Corresponding p-
values are indicated. N/A – not assessed, as only cell pools were used as reference samples. FU – fluorescence units. 
 
More importantly, samples processed with PCR-T2 provided higher signal intensities and 
lower signal-to-noise ratios following the aCGH hybridization indicating better performance 
of the method in the aCGH experiments. To determine true positive CNAs, resulting aCGH 
profiles of single-cell WGA products were compared to the corresponding profile generated 
by using unamplified genomic DNA of PT-1590 cells. In all specimens tested, single-cell 
aCGH profiles generated following the PCR-T1 labeling were less concordant to unamplified 
DNA than corresponding profiles generated using PCR-T2 (Figure 6 A-B). Higher accuracy 
of the latter approach was confirmed in the subsequent analysis of ROC curves (Figure 6C). 
Direct comparison bulk DNA revealed that multiple genomic alteration present in the bulk 
DNA were detectable in single-cell WGA products only upon utilization of PCR-T2 (Figure 
6D). It was speculated that the poorer sensitivity of aCGH following the PCR-T1 is associated 
with the unspecific hybridization of the adaptor sequences to the probes one the array. This 
would particularly affect short amplicons, i.e. shorter than <100 bp, where PCR adapters 
comprise a significant part of the amplification product. To minimize the bias introduced by 
the unspecific hybridization of the PCR-adaptor sequence, 100x or 1000x excess of unlabeled 
complimentary oligonucleotides were added into the hybridization mix. This intervention, 
however, gradually decreased the sensitivity and the reliability of the method by abrogating 
the detection of otherwise detectable alterations and resulted in introduction of artefacts 
(Figure 7). Consequently, due to poorer sensitivity of the aCGH the use of PCR-T1 was 
discontinued and PCR-T2 became the method of choice for the DNA labeling of WGA 
products. 
Results 
56 
 
Figure 6.  
 
Selection of best performing PCR-based labeling technique. 
A,B) Exemplary horizontal aCGH profiles of PT-1590 oesophageal cancer cells (A) or healthy female donor (B). 
Unamplified gDNA (upper panel) was used as benchmark and compared with the corresponding results obtained with a 
single-cell WGA product processed with either PCR-T1 (middle panel) or PCR-T2 (lower panel). All samples were 
hybridized against DNA samples (cell pool WGA products) originating from a healthy male. Deviations between the aCGH 
profiles of unamplified gDNA and single-cell WGA products are indicated by red arrows. X-axis genomic position. Y-axis 
log2 ratio of the normalized fluorescence values obtained for test and reference samples. DNA gains and losses are indicated 
by positive and negative log2 ratio values, respectively. 
C) ROC-curves comparing the accuracy of single-cell aCGH upon application of PCR-T1 (blue lines) and PCR-T2 (red lines) 
on a single-cell WGA product depicted in panel A. Accuracy of detection of DNA gains and losses are depicted separately 
with solid and dashed lines, respectively. ROC analysis was performed based on the genome-wide patterns of CNAs with 
unamplified gDNA of PT-1590 cells used as reference. A larger area under the curve (AUC) indicates higher accuracy of the 
method.  
D) Vertical aCGH profiles of chromosome 8 of PT-1590 cells (placed in violet bracket in panel A) generated with 
unamplified DNA (left panel) and single-cell WGA products processed with either PCR-T1 (middle panel) or PCR-T2 (right 
panel). Arrows indicate genomic loci falsely recognized as balanced in the sample subjected to PCR-T1 protocol. Genomic 
gains and losses are maked with red and green color, respectively, on the ideograms depicted on the left side of each panel. 
Discrepancies in the aCGH profiles are indicated with red arrows. 
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Figure 7. 
 
Blocking the hybridization of PCR-adaptor sequences present in the products of PCR-T1 DNA labeling. 
A, B) Horizontal aCGH profiles depicting single-cell WGA product of a PT-1590 cell (A) or a healthy female donor 
processed with PCR-T1. Hybridization of the PCR-adapter sequences on the aCGH probes was blocked by the addition of 
100x or 1000x excess of the unlabeled complementary DNA oligomere. Green arrows indicate false positive CNAs 
introduced by the addition of unlabeled primer sequences, whereas red arrows show genomic loci at which true positive 
CNAs were falsely classified as balanced intervals. 
 
3.1.2. Comparison of the PCR-T2 approach with the random primed isothermal 
amplification DNA labeling system (RP labeling). 
3.1.2.1.  Analysis of freshly isolated, unfixed cells. 
DNA labeling based on random primed isothermal amplification is the widest used system in 
two-color aCGH experiments. This system utilizes Klenow fragment of the Escherichia coli 
DNA polymerase I, which following the priming of random octamers facilitates incorporation 
of modified nucleotides into the target DNA [174]. In the past, this system already has been 
successfully applied to label single-cell WGA products [136-139,150,152,153,156,175,176]. 
In a recent publication Möhlendick and co-workers demonstrated that combined use of 
SCOMP with RP-labeling allows detection of CNAs in single cells with resolution of 100 kb 
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or less [146]. This protocol was directly compared with the PCR-T2 to stringently test the 
performance of the newly developed DNA labeling technique. To this end, freshly picked 
single cells of OE-19 esophageal cancer cell lines were subjected to SCOMP and 
subsequently processed in parallel by both PCR-T2 and RP-labeling. The OE-19 cell line is 
known to harbour complex patterns of genomic aberrations including focal homozygous DNA 
loss of ADAM3A locus (0.1 Mb in size) on chromosome 8 and amplification of ERBB2 locus 
(0.1 Mb in size) on chromosome 17 (http://www.broadinstitute.org/ccle/home) [177].  
 
Figure 8. 
 
Comparison of PCR-T2 with RP-labeling on cell line cells. 
A, B) Horizontal aCGH profiles of OE-19 cells generated using unamplified gDNA (A) or single-cell WGA products 
processed with either PCR-T2 (B, upper panel) or RP-labeling (B, lower panel).  
C) ROC-curves assessing the accuracy of the single-cell aCGH upon using PCR-T2 (blue lines) and RP-labeling techniques 
(black lines). Genome-wide pattern of CNAs of single-cell WGA products was compared against the aCGH resuts generated 
with unamplified gDNA of OE-19 cells. Area under the curve (AUC) corresponds to the accuracy of the assay. 
D, E) Vertical aCGH profiles of chromosome 8 (D) and chromosome 17 (E) of OE-19 cells. Left and middle panel depicts 
aCGH profiles generated using unamplified gDNA and single-cell WGA products labeled using PCR-T2, respectively. Right 
panel displays a graphical magnification of the loci in which CNAs were recognized.  
 
 
Regardless, of the labeling approach used, aCGH profiles of single OE-19 cells were highly 
concordant with the results obtained with unamplified bulk genomic DNA (Figure 8 A-C). 
Significantly, in both cases both labeling techniques allowed reliable and reproducible 
detection of CNAs as small as 100 kb (Figure 8 D-E). This indicated that PCR-T2 and RP-
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labeling are equally reliable for the detection of CNAs in single-cell WGA products generated 
from freshly isolated, unfixed material. 
 
3.1.2.2.  aCGH analysis of cells after immunostaining. 
Detection of DCCs is typically conducted with the use of immunostaining assays targeting 
epithelial markers e.g. CKs 8/18/19 [178]. These protocols comprise the use of fixative 
agents, e.g. paraformaldehyde, that negatively affect the quality of single-cell DNA. 
Consequently, the analytic workflows used for the analysis of DCCs must be highly resistant 
to bias introduced during the course of sample processing. To determine the most robust 
workflow for immunostained cells both RP-labeling and PCR-T2 were applied on DCCs from 
two prostate cancer patients. Additionally, single cells from the peripheral blood of five 
healthy donors (three females and two males) were isolated and used as controls. Since 
leukocytes of healthy individuals do not express CKs, these cells were stained for vimentin 
utilizing the same immunocytochemistry staining protocol as used for detection of DCCs. 
Following the immunostaining, single marker positive cells were picked and subjected to 
WGA and subsequently analysed by aCGH. Analysis of the aCGH profiles of control cells 
revealed in all tested samples presence of focal shifts of log2 ratio values manifested as both 
DNA gains and losses ranging from 0.1 to 20.7 Mb in size (Figure 9 A-B). Since their 
distribution was random and their detection was independent of the DNA labeling protocol 
used, these aberration calls were classified as artefacts. To prevent their detection, the 
standard settings for the alteration detection algorithm (ADM-2) and the minimum absolute 
log2 ratio of aberrant regions were modified to 7.0 and 0.3, respectively (Figure 9 A-B). Since 
the average length of detected artificial CNAs was longer in samples processed with the RP 
labeling (Student’s t-test P<0.05), modification of the aberration filter proved to be more 
effective for specimen subjected to the PCR-T2 labeling (Figure 9 A-B). Elimination of 
artefacts generated by the RP-labeling required the use of high threshold values for the 
absolute average log2 ratios of aberrant regions (>0.5) or the ADM-2 aberration algorithm 
(>11.5). However, this strongly reduced sensitivity of the assay (Figure 9 C-D). Due to the 
discrepancies in the sensitivity of the single-cell aCGH assay depending on the DNA labeling 
technique used, the use of RP-labeling was abandoned and PCR-T2 was utilized for all further 
aCGH experiments involving single-cell WGA products. 
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Figure 9. 
  
Comparison of PCR-T2 with RP-labeling on prostate cancer DCCs and lymphocytes of healthy donors. 
A-B) Horizontal aCGH of a single-cell WGA obtained from a control cell (vimentin positive) of a healthy female donor 
processed with PCR-T2 (A) or RP-labeling (B). Analytical settings were varied to allow elimination of false positive CNAs. 
C-D) Horizontal aCGH of a single-cell WGA generated from a DCC of a prostate cancer patient and subjected to PCR-T2 
(C) or RP-labeling (D).  
Green arrows indicated artificial alterations detected in single-cell WGA products, whereas red arrows show CNAs which 
escaped detection upon adjustment of the analytical settings to remove the artificial aberration calls. 
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3.1.3. Reproducibility of the single-cell aCGH analysis. 
Reliable assays designated for the analysis of clinical patient material should provide highly 
reproducible data. To assess the reproducibility of the single-cell aCGH assay, WGA products 
of PT-1590 cell, were repeatedly hybridized on aCGH arrays as technical replicates. Repeated 
hybridization of single-cell WGA products processed with PCR-T2 gave highly reproducible 
results, with the correlation coefficient (cxy) of log2 ratios across different experiments 
ranging from 0.897 to 0.948 (Figure 10).  
 
Figure 10. 
 
 
Reproducibility of the single cell aCGH assay using PCR-T2 labeling approach. 
A,B) Horizontal aCGH profiles of WGA products generated using either cell pool (A) or single-cell (B) WGA products of 
PT-1590 oesophageal cancer cell line cells. Each profile represents a technical replicate of an aCGH experiment. 
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3.1.4. Selection of the best performing type of reference sample. 
The applied reference sample is a crucial component of every aCGH experiment. Since CGH 
compares the relative amounts of DNA in the two samples, i.e. test and reference, aberrance 
in DNA quantity or quality between test and reference sample may introduce systematic bias, 
thereby making the detection of CNAs unreliable. For this reason two types of samples were 
tested for their applicability as reference in single-cell aCGH experiments: (i) WGA products 
generated from cell pools (approximately 100-1000 cells) and (ii) samples obtained by 
pooling four independently amplified single-cell WGA products. In both cases, cells were 
collected from the mononuclear fraction of peripheral blood of healthy male or female donors. 
Both types of references were used in subsequent aCGH experiments and hybridized against 
single-cell WGA products of PT-1590 cell lines or a healthy female donor. Direct comparison 
of the resulting aCGH profiles revealed that derivative log2 ratio spread (DLRS) values, a 
measurement of hybridization noise, were consistently higher in testing series using cell pool 
WGA product as reference DNA compared to experiments utilizing reference samples 
consisting of amplified single-cell DNA (average DLRS 0.85 and 0.55, respecitively, Figure 
11).  
 
Figure 11. 
 
Selection of the best performing reference DNA sample. 
A, B) Horizontal aCGH profiles of single-cell WGA products generated with either a PT-1590 cell (A) or a cell isolated from 
a healthy female donor (B). Test samples were hybridized against either WGA products generated from cell pool (upper 
panels) or a pool of four single-cell WGA products (lower panels). Green arrows indicate CNAs detected exclusively upon 
utilization of single-cell WGA products as reference DNA. 
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Reduced level of technical noise of the hybridization upon application of reference samples 
consisting of single-cell WGA product enabled detection of additional CNAs which otherwise 
would remain undetected when cell pool based reference was utilized (Figure 11). As a 
consequence all subsequent experiments included a pool of four single-cell WGA products 
originating from one healthy individual as a reference sample.  
 
3.1.5. Suitability of re-amplified single-cell WGA product for high resolution 
aCGH . 
WGA techniques provide sufficient amounts of DNA material for multiple downstream 
analysis. Nevertheless, the yield of each WGA is limited, which may preclude some high-
throughput analyses, e.g. whole genome sequencing, where large amount of input material is 
needed. One of the ways to increase the DNA yield originating from a single-cell is to subject 
the primary WGA to a second round of amplification (re-amplification). PCR-based WGA 
approaches utilizing non-degenerated primer during the exponential phase of amplification, 
e.g. SCOMP, GenomePlex, PicoPlex and MALBAC, enable comprehensive re-amplification 
of the entire single-cell genomic representation. However, the additional round of 
amplification may introduce bias into the original sample representation noticeable as e.g. 
false positive CNAs in the aCGH analysis. To exclude the introduction of artificial CNAs by 
the second round of WGA amplification, primary WGA products need to be directly 
compared with the re-amplified counterparts. For this purpose, single-cell WGA products 
originating from OE-19 cells or from healthy donors were analysed by aCGH. The aCGH 
profiles generated with re-amplified single-cell WGA products showed a high level of 
concordance with the corresponding results obtained with unamplified DNA (Figure 12A). 
Subsequent ROC analysis confirmed highly accurate detection of CNAs in OE-19 cells with 
the use of re-amplified WGA products (Figure 12B). Moreover, re-amplified single-cell WGA 
products obtained from healthy donors showed balanced aCGH profiles (Figure 12C). This 
indicates that second round of amplification does not introduce significant amplification bias 
into the original DNA representation and its use does not affect the outcome of the aCGH 
analysis. For this reason, all subsequent aCGH experiments were constricted to re-amplified 
WGA products only. 
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Figure 12. 
 
Suitability of re-amplified WGA products for single-cell aCGH. 
A) Horizontal aCGH profiles of primary (upper panel) or re-amplified WGA products (lower panel) of a single OE-19 cell. 
B) ROC curves comparing the accuracy of the single-cell aCGH assay after analysis of primary (blue lines) and reamplified 
WGA products (brown lines). Corresponding aCGH profiles are depicted in panel A. Genome-wide pattern of CNAs of 
single-cell WGA products was compared against the aCGH products generated with unamplified gDNA of OE-19 cells. Area 
under the curve (AUC) corresponds to the accuracy of the assay. 
C) Horizontal aCGH profile of a healthy male donor hybridized against male reference DNA. 
 
3.2. Performance of the high-resolution single-cell aCGH assay. 
3.2.1. Detection of genomic heterogeneity between individual cells. 
High level of genomic diversity is considered as the hallmark of benign tumor lesions, which 
enables the selection of cells or cellular clones bearing the most aggressive phenotype leading 
to malignant progression of the disease [97]. Unravelling the evolution of early tumor lesions 
is dependent on the sensitivity of the method used to assess the extent of genomic diversity 
within the sampled specimens. These, have to be able to reliably detect genomic discrepancies 
between tumor cell clones or, ideally, distinguish between individual tumor cells. To this end 
it was important to validate the ability of the new single-cell aCGH assay to detect genomic 
heterogeneity at the single-cell level. Previous studies have shown that at the single-cell level 
PT-1590 oesophageal cancer cells show detectable genomic heterogeneity [92,173]. 
Therefore, previously generated single-cell aCGH datasets (see sections 3.1.1., 3.1.3. and 
3.1.4) were reanalysed, in an attempt to identify genomic discrepancies between the 
individual PT-1590. Subsequent analysis showed that the majority of detected genomic 
aberrations were common to all of the samples, e.g. DNA gains of chromosome 6 and 7, DNA 
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Reamp WGA – gain: AUC = 0.99
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A
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loss of chromosome 5q11.2-5q14.2 as well as complex pattern of gains and losses on 
chromosome 8 (Figure 13A). However, some aberrations, e.g. DNA gain on chromosome 
17p13.1 in single-cell 1, DNA loss of chromosome 17q24.3-25.1 in single-cell #2 and DNA 
gain on chromosome 17q22 in single-cell #3, were present only in individual cells but not in 
the bulk genomic DNA (Figure 13B).  
 
Figure 13. 
 
Detection of single cell heterogeneity. 
A) Horizontal aCGH profiles generated using either unamplified gDNA or single-cell WGA products of PT-1590 cells. 
Red arrows show genomic loci at which the single-cell WGA profiles diverged from the results obtained for unamplified 
genomic DNA. 
B) Magnified vertical aCGH profiles of chromosome 17 of samples presented in the panel A. 
Red arrows indicate discrepancies in the aCGH profiles of single PT-1590 cells and green arrows indicated localization of the 
ERBB2 locus. 
C) Representative FISH images of PT1590 cells. Red signals indicate ERBB2 locus and green CEP17. White arrows label 
cells with balanced copy number of ERBB2 vs. CEP17. Yellow arrowhead shows cells with high-level amplification of the 
ERBB2 locus. 
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Despite previous reports indicating the relevance of the ERBB2 amplification in the PT-1590 
cells [21], one out of three tested PT-1590 cells did not harbour this alteration (Figure 13B). 
To exclude artificial character of this observation, PT-1590 cells were analysed by FISH 
targeting centromere of chromosome 17 as well as ERBB2 locus, showing that 10% of PT-
1590 cells display balanced copy number of the ERBB2 locus (Figure 13C). Thus, CNAs 
detected in the individual cells but not the bulk DNA could represent true positive alterations 
that affect only these particular cells or small cellular subfractions and thereby remained 
undetectable for the standard aCGH analysis. 
 
3.2.2. Quantitative assessment of CNAs in the single cells. 
It is expected that a reliable assay for the assessment of CNAs in single-cell will be able to 
accurately quantify the level of copy number changes of a given loci. For this reason, the new 
single-cell aCGH assay was tested for its precision to quantify various levels of copy number 
changes. To this end, bulk DNA and single-cell WGA products from a panel of four breast 
cancer cell lines (MDA-MB-453, MDA-MB-361, SK-BR-3 and BT-474) were tested for 
accuracy of the copy number assessment at the ERBB2 locus. With FISH ratios of ERBB2 to 
CEP17 ranging from 2.15 to 5.79, each cell line included in the analysis represented a 
different copy number of the ERBB2 locus (Figure 14A). The average log2 ratios of probes 
specific for ERBB2 locus obtained in single-cell experiments were extracted and correlated 
with the corresponding values acquired from the unamplified DNA and the ratios of ERBB2 
to CEP17 obtained in the FISH experiments (Figure 14 B-C). In both comparisons, single-cell 
aCGH vs. standard aCGH and single-cell aCGH vs. FISH, the measures of the ERBB2 copy 
number were highly convergent showing Pearson’s correlation coefficient of 0.99 and 0.94, 
respectively (Figure 14 B-C). This shows that in the copy number range of 2 to 10 copies, 
single-cell aCGH workflow allows accurate quantitative assessment of CNAs. 
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Figure 14. 
 
Quantitative assessment CNAs by the new single-cell aCGH assay. 
A) Vertical aCGH profiles of chromosome 17 of four breast cancer cell lines (MDA-MB-453, MDA-MB-361, SKBR3 and 
BT474) with increasing copy number of ERBB2 locus (FISH ratio 2.15, 3.60, 4.42 and 5.70, respectively) generated using 
unamplified DNA (upper row) or single-cell WGA products (lower row). Red brackets indicate the position of the ERBB2 
locus. Corresponding FISH ratios (ERBB2 vs. CEP17) of all cell lines are indicated in blue brackets. 
B) Correlation of average log2 values of aCGH probes specific for ERBB2 locus obtained in single-cell aCGH experiments 
(Y-axis) vs. corresponding values obtained with unamplified DNA (X-axis). DNA samples from four breast cancer cell lines 
(MDA-MB-453, MDA-MB-361, SKBR3, BT474) have been included in the analysis. Pearson’s correlation coefficient = 
0.99. 
C) Correlation of average log2 values of aCGH probes specific for ERBB2 locus obtained in single-cell aCGH experiments 
(Y-axis) vs. FISH ratios (ERBB2/CEP17) calculated for four breast cancer cell lines: MDA-MB-453, MDA-MB-361, 
SKBR3, BT474. Pearson’s correlation coefficient = 0.94. 
 
 
 
MDA-MB-453
FISH Ratio: 2.15
MDA-MB-361
FISH Ratio: 3.60
SKBR3
FISH Ratio: 4.42
BT474
FISH Ratio: 5.79
g
D
N
A
S
in
g
le
-C
e
ll
E
R
B
B
2
E
R
B
B
2
A
B C
Results 
68 
 
3.2.3. Comparison with previously available methods for single-cell CGH. 
Previously, single-cell WGA products generated with SCOMP have been already analysed 
using metaphase CGH (mCGH) and BAC-based aCGH arrays [47,145]. The later approach 
allowed detection of CNAs in breast cancer DCCs as small as 4.4 Mb in size. More recently, 
the detection limit of this method was further increased by the application of tiling resolution 
BAC-based aCGH platform ([170], unpublished data). To demonstrate the performance of the 
new aCGH workflow for the analysis of DCCs, the new method was compared with the 
previously used analytical approach based on mCGH. To this end, two prostate cancer DCCs 
previously analysed by mCGH were now re-analysed using the new high-resolution 
oligonucleotide arrays. Direct comparison between the results obtained using mCGH and the 
new aCGH-based workflow showed high level of concordance. However, in one of the 
prostate cancer DCCs several focal alterations escaped the detection by mCGH indicating 
higher sensitivity of the aCGH-based approach, e.g. DNA losses of chromosome 1p35.3-35.2, 
3q12.2-13.11 and 6p21.33-21.31 (Figure 15). With sizes of 3.5 Mb, 3.4 Mb and 2.4 Mb, 
respectively, these aberrations were beyond the level of detection provided by the mCGH-
based approach. To additionally challenge the new assay, its performance was directly 
compared with a recently developed single-cell aCGH approach using array design consisting 
of chromosome 17 specific tiling resolution BAC clone library [170]. Due to the specific 
design of the BAC clone-based arrays, the comparison of the aCGH platforms was restricted 
to chromosome 17 only. Four oesophageal cancer DCCs were selected for the comparison of 
the aCGH platforms. These specimens were previously analysed using BAC clone-based 
aCGH, mCGH and a qPCR assay. Using qPCR it was possible to detect amplification of the 
ERBB2 locus in two analysed cells (3266 Lk4T2 and 3270 Lk6T2). Consistently with the 
results of qPCR, single-cell mCGH and oligonucleotide aCGH but not BAC clone-based 
aCGH detected copy number gains in a genomic region encompassing the ERBB2 locus on 
chromosome 17q12 (Figure 16). Furthermore, in all samples tested BAC clone-based aCGH 
failed to detect CNAs, which were otherwise identified by mCGH and the new 
oligonucleotide aCGH assay (Figure 16). Significantly, the latter two approaches provided 
very concordant profiles of copy number changes, although the boundaries of CNAs could be 
detected more precisely using the oligonucleotide aCGH, thereby showing higher sensitivity 
of this approach (Figure 16). Collectively, these results indicate that the single-cell aCGH 
assay using oligonucleotide arrays provides more accurate assessment of CNAs than mCGH 
and the aCGH approach using BAC clone-based arrays. 
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Figure 15. 
 
Comparison of the new single-cell aCGH workflow with the mCGH based approach. 
A) Exemplary vertical single-cell mCGH (left panel) and aCGH (right panel) profiles of a DCC of a prostate cancer patient. 
In the mCGH plots, DNA gains and losses are indicated by red or green bars, respectively. CNAs detected by aCGH are 
indicated by gray shading depicted in the profiles. 
B, C, D) Horizontal mCGH (left panel) and aCGH profiles of chromosome 1, 3 and 6 of the prostate cancer DCC depicted in  
panel A. Black arrows indicate CNAs which were detected by aCGH and escaped detection by mCGH. 
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Figure 16. 
 
Comparison of single-cell aCGH approaches based on patient derived DCCs.  
Vertical mCGH (upper row) or aCGH profiles generated using either a BAC clone-based (middle row) or oligonucleotide 
(lower row) platform. Only chromosome 17 specific profiles of four oesophageal cancer cells are depicted. Red arrows 
indicate the location of the amplified ERBB2 loci in the depicted cells. Black arrows show locations at which BAC clone-
based aCGH assay failed to detect CNAs. 
 
3.3. Application of the new single-cell aCGH assay to the analysis of single DCCs. 
Tumor heterogeneity and the resulting clonal evolution pose a challenge for molecular 
diagnostics and treatment of cancer. DCCs or CTCs have the potential to be used for 
monitoring the progression of malignant disease. Molecular analysis of these cells at different 
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time points of disease could allow to control the tumor burden more efficiently, monitor the 
process of clonal selection and study the mechanism of drug resistance. In a proof-of-
principle study the new single-cell aCGH assay was used to demonstrate the utility of DCCs 
to monitor the clonal evolution of cancer cells during the malignant progression. For this, a 
breast cancer patient was selected who was consecutively tested for the presence of DCCs 
throughout the course of treatment. The patient was diagnosed initially with advanced, stage 
IV breast cancer (PT4b, N1bii, pM1, G3, ER+, PR+, HER2-), with metastatic lesions detected 
in the lymph nodes and bones. During the subsequent eleven months the patient was subjected 
to high dose chemotherapy treatment (Figure 17A). During this time the presence of DCCs 
was quantified four times: once at the time point of the primary tumor resection (July 1998) 
and three consecutive times during the course of treatment (September 1998, November 1998 
and July 1999) (Figure 17B). The DCC count (DCC/1x10
6
 white blood cells) was steadily 
decreasing, with 102, 73, 8 and 3 detected DCCs, respectively (Fig 17B). This indicated that 
the tumor burden decreased as a consequence of the administered treatment. Two single 
DCCs from each of the time points were subjected to WGA and subsequently analysed by 
aCGH. Additionally, the analysis included two formalin FFPE tumor tissue specimens; one 
from the primary tumor and the other from the lymph node metastasis. Investigation of the 
resulting aCGH profiles revealed multiple CNAs in all samples tested (Figure 17C). Further 
analysis revealed forty one minimal regions of common aberration (MRAs) (Figure 17D). 
Nineteen aberrant regions (both DNA gains and losses) were found in DCCs only, no CNAs 
were found to be specific for the metastatic lesion and only one CNA was detected 
exclusively in the primary tumor (Table 20, Figure 17D). This indicates that DCCs may 
represent a more advanced stage of the disease. Among the remaining MRAs, nine were 
found present in the metastatic compartment (metastatic lesion and DCCs) but not in the 
primary tumor (Table 20, Figure 17D). Interestingly, this group included genomic losses only 
(Table 20) indicating that these regions may harbour metastatic suppressor genes. Further 
analysis of the aCGH datasets revealed six MRAs shared by samples representing all analysed 
sites (primary tumor, metastatic lesion and at least one DCCs) (Table 20, Figure 17D). Within 
this group four aberrant regions were present in all tested specimens – gains on 17q and 8q 
and losses on chromosomes 6 and 13 (Figure 17E). These regions harbour multiple oncogenes 
and tumor suppressor genes, e.g. MYC, MTDH and RB1, that were previously associated 
with the progression of breast cancer. High penetrance of CNAs in these regions suggests that 
these aberrations were among the earliest genomic events that had occurred during the course 
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of the cancer progression of the studied case. Subsequent hierarchical clustering based on the 
cytogenetic profiles of the collected samples revealed clonality of DCCs (Figure 17F).  
 
Figure 17. 
 
Molecular findings in individual DCCs during the course of high dose chemotherapy treatment. 
A) The overview of the chemotherapy treatment. The patient was first subjected to three cycles of 75mg/m2 Taxotere® and 
50mg/m2 Doxorubicin (TD) in three week intervals. Subsequently, followed two cycles of high dose chemotherapy treatment 
with an intermediate interval of 4-6 weeks. In the first cycle 500mg/m2 of Vepesid (V), 4000mg/m2 of Isofamid (I) and 
500mg/m2 of Carboplatin (C) was administered. The last cycle consisted of 1500mg/m2 of Cyclophosphamid (Cy) and 
200mg/m2 of Thiotepa (T). Both cycles of high dose chemotherapeutic treatment were accompanied by addition of 
granulocyte colony-stimulating factor (G-CSF) and autologous transplant of peripheral blood stem cells (PBSCs). 
B) The course of bone marrow sampling. DCC count indicate the amount of detected DCCs in 1.0x106 mononuclear cells. 
C) Horizontal aCGH profile of samples included in the study: primary tumor, lymph node metastasis and eight DCCs. 
D) Venn diagram depicting the amount of MRAs (both gains and losses) detected in all three types of clinical samples. 
E) Table depicting core MRAs that were detected with 100% penetrance across all the analysed samples. 
F) Hierarchical clustering (distance: Euclidian; linkage: average) of samples included in the aCGH analysis. 
 
The analysis showed two major sample clusters: (i) containing the metastatic tissue and 7 of 8 
tested DCCs and (ii) consisting of the remaining DCC (DCC #1, time point 3) and primary 
lesion. Strikingly, the DCC contained in the second cluster harboured the lowest amount of 
genomic alteration indicating that this cell represented the earliest stage of the tumorigenic 
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progression among tested specimens. Lack of otherwise recurrent CNAs was also detected in 
the DCC #2 collected at the time point 4 (Figure 17C). Collectively, this proof-of-principle 
study shows that the new assay is well suited to monitor the clonal selection of DCCs 
throughout the course of cancer treatment. 
 
Table 20. 
Minimal regions of recurrent copy number changes. 
 
# Chr Name Aberration size [Mb] Gain/Loss Sample type
Penetrance 
All Samples
Penetrance 
DCCs only
Cytoband
1 chr6 99,6 Loss PT+Met+DCCs 100 100 6q12-27
2 chr8 68,7 Gain PT+Met+DCCs 100 100 8q13.1-24.23
3 chr13 27,4 Loss PT+Met+DCCs 100 100 13q14.11-21.33
4 chr16 35,1 Loss PT+Met+DCCs 90 87,5 16q12.2-24.2
5 chr17 14,2 Gain PT+Met+DCCs 100 100 17q22-25.1
6 chr22 26,8 Loss PT+Met+DCCs 90 87,5 22q11.21-13.31
7 chr1 35,1 Loss DCCs 10 12,5 1p36.12-32.1
8 chr4 6,2 Loss DCCs 10 12,5 4q13.1-13.2
9 chr4 14,7 Loss DCCs 10 12,5 4q22.1-25
10 chr5 34,5 Gain DCCs 70 87,5 5q21.3-35.3
11 chr9 14,1 Loss DCCs 70 87,5 9p21.11-21.32
12 chr10 1,9 Loss DCCs 20 25 10p15.3-15.2
13 chr11 25,3 Loss DCCs 20 25 11p14.3-11.12
14 chr11 11,6 Loss DCCs 20 25 11q12.1-13.3
15 chr12 24,8 Loss DCCs 80 100 12p13.33-11.23
16 chr12 2,4 Loss DCCs 10 12,5 12q21.31
17 chr15 14,0 Loss DCCs 30 37,5 15q24.1-25.3
18 chr15 8,4 Gain DCCs 30 37,5 15q26.1-26.3
19 chr17 6,9 Loss DCCs 20 25 17q11.2-12
20 chr18 4,1 Loss DCCs 10 12,5 18p11.31-11.23
21 chr19 19,7 Loss DCCs 10 12,5 19q13.2-13.43
22 chr20 28,3 Gain DCCs 70 87,5 20q11.22-13.33
23 chr21 6,8 Loss DCCs 30 37,5 21q11.2-21.1
24 chrX 7,4 Loss DCCs 20 25 Xq11.1-13.1
25 chrX 17,4 Gain DCCs 40 50 Xq26.2-28
26 chr18 58,3 Gain PT 10 0 18q11.1-23
27 chr1 22,7 Gain PT+DCCs 80 87,5 1q24.1-31.1
28 chr1 10,0 Gain PT+DCCs 80 87,5 1q41-42.12
29 chr4 12,3 Gain PT+DCCs 30 25 4q21.21-22.1
30 chr8 8,6 Gain PT+DCCs 20 12,5 8p23.3-23.1
31 chr9 33,5 Gain PT+DCCs 60 62,5 9p22.33-34.1
32 chr11 43,4 Loss PT+DCCs 80 87,5 11q14.3-25
33 chr3 35,9 Loss Met+DCCs 80 87,5 3p21.31-p12.2
34 chr6 11,8 Loss Met+DCCs 80 87,5 6p25.3-24.1
35 chr8 25,4 Loss Met+DCCs 80 87,5 8p22-11.22
36 chr9 29,4 Loss Met+DCCs 90 100 9p24.1-13.3
37 chr10 7,2 Loss Met+DCCs 50 50 10q21.1-21.2
38 chr14 10,5 Loss Met+DCCs 90 100 14q24.1-31.1
39 chr17 12,4 Loss Met+DCCs 80 87,5 17p13.2-11.2
40 chr18 39,5 Loss Met+DCCs 80 87,5 18q12.3-23
41 chrX 43,4 Loss Met+DCCs 90 100 Xp22.33-11.3
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4. Discussion. 
4.1. Development of a high-resolution aCGH assay for accurate mapping of 
genomic aberrations in single cells.  
The aim of this study was to develop a novel method for robust and accurate assessment of 
copy number aberrations in the genomes of single micrometastatic cancer cells. To facilitate 
this goal, a novel aCGH protocol was established allowing reliable detection of copy number 
aberrations as small as 100 kb in single-cell genomes. Critical for achieving this level of 
accuracy were the following factors: (i) the use of high-resolution aCGH arrays, (ii) 
application of highly robust SCOMP WGA technology, and (iii) improvements of the 
experimental procedures for labeling and hybridization of WGA products. 
 
4.1.1. Selection of the most suitable aCGH platform. 
Reports published before the beginning of the research project outlined in this thesis indicated 
that the outcome of single-cell aCGH is highly dependent on the design and quality of the 
DNA arrays used for the analysis. A study published by Fuhrmann and coworkers showed 
that depletion of contaminating bacterial DNA from BAC probes by pulse field gel 
electrophoresis (PFGE) significantly improves the performance of BAC arrays for single-cell 
aCGH, allowing detection of CNAs at 1-2 Mb resolution [145]. At that time, this platform 
outperformed all traditional BAC-based and oligonucleotide arrays in terms of sensitivity. 
However, the laborious fabrication of PFGE-purified BACs [145] and generally low spatial 
resolution of BAC-based arrays [179] hindered the widespread use of this technology. An 
opportunity to improve the sensitivity of single-cell aCGH came with the development of 
technologies for in situ synthesis of DNA oligonucleotides on solid surfaces, enabling 
fabrication of high-resolution arrays [180-182]. In recent years oligonucleotide arrays have 
been applied in multiple studies analysing single-cell WGA products 
[137,139,150,153,156,183-188]. However, despite higher probe density of oligonucleotide 
arrays the sensitivity of resulting single-cell aCGH assays remained inferior to best 
performing BAC-based platform [145] suggesting that the detection limit of single-cell aCGH 
had been reached. Only very recently, reports including the study presented here indicated 
that a reliable detection of CNAs of 1 Mb or smaller is possible using the modern high-
resolution oligonucleotide arrays [144,146,156]. Strikingly, these studies utilized oligoarrays 
manufactured by using the inkjet deposition technology, which suggests that this type of 
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aCGH platform offers the highest level of accuracy. Indeed, recent reports showed that 
oligonucleotide arrays generated using inkjet deposition approach allow the most sensitive 
detection of copy number variations [189,190]. Another explanation for the improved 
performance of single-cell aCGH in the last studies may be associated with the advances in 
probe design algorithms and in silico probes selection criteria [191-193]. Previous reports 
suggested that that sensitive detection of copy number variations in single-cell WGA products 
is only possible when using arrays with ultra-high density (median probe spacing of 65-80 bp) 
[137,156]. In contrast, data presented in this thesis and the work of others [146] show that 
arrays with median probe spacing of 13 kb provide already sufficient resolution for precise 
copy number profiling in single-cell genomes, indicating that performance of individual 
probes have increased in comparison with previously used platforms. Collectively, these data 
indicate that selection of both the array platform and design of probes may be critical for 
performance of single-cell aCGH. 
 
4.1.2. Selection of WGA technology. 
A second important factor influencing the accuracy of copy number profiling is the selection 
of the WGA approach to amplify single cell genomes. Recent reports based on data collected 
by single-cell aCGH or whole genome sequencing showed that PCR-based WGA approaches, 
e.g. GenomePlex and PicoPlex, allow more accurate detection of CNAs than MDA-based 
WGA technologies [120,141,194]. Although the nature of this phenomenon is not fully 
understood, it seems possible that sequence artefacts and quantitative amplification bias 
introduced in MDA products may pose putative causes for distort copy number profiles of 
single-cell MDA products [118,120]. Moreover, due to inherent characteristics of primer 
design and reduced efficiency to amplify short DNA molecules, MDA seem to be less suitable 
for analysis of partially degraded, or otherwise fragmented, templates such as DNA extracted 
from FFPE tissue specimens, thereby limiting the applicability of this method to clinical 
samples [114,124,151]. In contrast, PCR-based approaches were shown to be able to 
efficiently amplify DNA from various types of archival clinical material [127,195,196]. 
Moreover, comparison of various PCR-based WGA methodologies, including GenomePlex, 
PicoPlex and SCOMP, revealed that the latter technology provides the most accurate single-
cell aCGH data suggesting that SCOMP is the most suitable WGA approach for assessment of 
copy number changes in single-cell WGA products [146]. In accordance, data presented in 
this thesis show that SCOMP allows highly reliable and accurate profiling of CNAs in single-
Discussion 
76 
 
cell genomes, suggesting that this WGA approach is highly suitable for high-resolution 
single-cell aCGH analysis. On the other hand, recent studies indicate WGA approaches 
employing MDA, in particular MALBAC, attain broader breadth of genomic coverage 
making them potentially more suitable for applications that are directed at accurate 
genotyping rather than copy number analysis [118,120,141]. 
 
4.1.3. Selection of a strategy for DNA labeling. 
Another technical factor that influenced the performance of single-cell aCGH is DNA 
labeling. Several techniques have been developed for DNA labeling, including nick 
translation [197,198], random priming (RP labeling) [199,200], non-enzymatic universal 
linkage system (ULS) [201,202] and direct labeling by PCR [145,203]. However, nick 
translation, RP-labeling and ULS require high input of DNA (typically ≥ 1 µg), which can be 
problematic if applied to unique and precious samples such as single-cell WGA products from 
micrometastatic cancer cells. To avoid excessive consumption of the WGA products two 
novel PCR-based DNA labeling approaches were developed designed specifically for WGA 
products generated by SCOMP (PCR-T1 and PCR-T2, see Figure 4 in Materials and methods 
section). The new methods require only minute quantities of DNA for labeling, leaving 
sufficient amount of material for multiple downstream applications, such as qPCR or next 
generation sequencing (NGS). However, direct comparison of both approaches revealed that 
PCR-T1 is susceptible to introduce amplification bias into the amplified DNA and therefore is 
not suitable for single-cell aCGH. This was most likely caused by illegitimate cross-
hybridization of adaptor sequences to the DNA probes on the array or suboptimal priming of 
the dye-conjugated oligonucleotide, indicated by low DNA yields. In contrast, analysis of 
single-cell WGA product labeled with PCR-T2 showed that this approach allows reliable and 
reproducible labeling of SCOMP WGA products without introducing any noticeable bias to 
the original genomic representation. Direct comparison of PCR-T2 with a RP labeling 
technique recently successfully applied to WGA product generated by SCOMP [146] showed 
that the new PCR-based technique allows more reliable assessment of CNAs in patient-
derived immunostained cells. Although the exact mechanism causing this phenomenon was 
not elucidated, it seems likely that poorer performance of RP labelling in clinical samples may 
be caused by shortening of the average length of WGA amplicons brought about by DNA 
breaks resulting from fixation and sample processing. Due to the use of random primers the 
products of RP labelling generated from short DNA fragments may carry insufficient amounts 
Discussion 
77 
 
of dye to be efficiently detected. In contrast, the design of PCR-T2 ensures comprehensive 
labeling of entire WGA amplicons allowing incorporation of higher amounts of dye into the 
short DNA fragments. As a consequence, PCR-T2 labeling approach facilitates more effective 
labelling of clinical samples, thereby making this method better suited for processing of 
patient-derived clinical specimens such as DCCs or CTCs.  
 
4.1.4. Selection of reference samples. 
A prerequisite for successful aCGH analysis is comparable representation of genomic 
sequences in both test and reference sample. However, all WGA procedures are prone to 
amplification bias [113,118,120,141,147,204] or generate DNA representations which in 
terms of complexity differ from the unamplified DNA [205,206]. Therefore, co-hybridization 
of test samples amplified by WGA with unamplified reference specimen may lead to 
increased hybridization noise or introduction of artefacts to aCGH data. Previous reports 
showed that bias introduced by hybridization of a single-cell WGA product against non-
amplified reference DNA may be compensated by using dedicated computational algorithms 
[153,207] or by matching the sample characteristics of test and reference DNA i.e. by 
amplifying both samples with the same WGA procedure [202]. Due to its simplicity the latter 
approach was used preferentially in the recently published single-cell aCGH analyses 
[137,139,145,146,156,185]. In many of these studies samples used as reference DNA 
consisted of WGA product generated from pooled cells [137,139,145]. However, data 
presented in this thesis showed that, in comparison to WGA product from cell pools, DNA 
obtained by pooling multiple single-cell WGAs is more suitable for single-cell aCGH analysis 
as this approach allows reduction of hybridization noise and thereby more confident 
recognition of copy number aberrations in single-cell WGA products. Similar observations 
were also made in a study by Bi and coworkers [156]. This indicates that proper selection of 
reference DNA has a strong impact on the performance of aCGH analysis.  
 
4.2. Advantages of the novel single-cell aCGH assay. 
The assay presented in this work proved to be highly reliable and accurate. Comparison of 
FISH and aCGH data revealed that the new assay allows accurate detection of CNAs over a 
wide dynamic range of copy number states. Remarkably, the high-quality data provided by 
the new method allowed detection of aberrations as small as 0.1 Mb in single-cell genomes. 
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However, it possible that even smaller genetic lesion (<0.1 Mb) could be also detected had 
they been present in tested cells. This level of sensitivity is superior to most of the available 
methods for array based profiling of CNAs in single cells and only comparable with the most 
sensitive single-cell aCGH assay currently available [146]. However, due to the use of RP-
labeling the latter methodology is less reliable if applied to single cells that were subjected to 
immunostaining prior to WGA. Further improvement of resolution may be achieved by 
application of single-cell methodologies based on NGS. A recently presented method based 
on pair-end high throughput sequencing allowed detection of CNAs as small as 13-35 kb 
[120] in single-cell genomes. However, only a small fraction of these events (12-26%) could 
be confirmed by presence of discordant read pairs and PCR. Notwithstanding, more confident 
recognition of CNAs by single-cell NGS would necessitate the use of recently emerging 
technologies for low-error high-throughput sequencing [208]. Beyond the high resolving 
power, the new assay proved to be remarkably robust providing consistently good quality data 
for all tested samples, including FFPE specimens and archival WGA products stored for more 
than 10 years. In comparison, recently presented single-cell aCGH workflow using MDA-
based WGA allowed analysis of only 59% of successfully amplified single-cell DNA samples 
[153,175]. Moreover, unlike to other single-cell aCGH workflows published in the past, 
evaluation of the data generated by the new method did not necessitate the use of customized 
scripts for data curation. Despite increased level of hybridization noise typical for single-cell 
WGA products, copy number aberrations could be identified using standard detection 
algorithms such as AMD-2 [209] or CBS [210]. Consequently, streamlined experimental 
design and automatable data evaluation makes the new protocol particularly user-friendly and 
amenable to routine use in molecular biology laboratories. Beyond that, the new assay 
presented here can be executed in a short amount of time. While the other protocols [175] 
require up to a week for completion of the analysis, the assay presented in this work can be 
executed within 2.5 day. Still, this timeframe is too long to apply the new method for prenatal 
genetic diagnosis (PGD), wherein the results need to be delivered within 48h to prevent 
cryopreservation of the embryo. 
 
4.3. Applicability of the new analysis to monitor genomic heterogeneity of clinical 
DCCs – proof-of-principle case report. 
Genetic heterogeneity of malignant diseases is recognized as a major obstacle for eradication 
of metastases and effective treatment of cancer [211-213]. It may have important clinical 
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implications for the diagnosis, treatment outcome and identification of putative drug targets 
[12,213-217]. Therefore, better understanding of the extent of the intratumor heterogeneity is 
of direct clinical importance. Increasing evidence indicate that efficacy of treatment may 
depend on the ability to detect rare genetically and functionally distinct tumor subclones that 
harbour driving mutations or confer resistance to treatment [138,211,213,216,218,219]. 
However, identification of such clones is technically challenging and would necessitate 
longitudinal sampling over the course of treatment [213]. Previously, presence of intratumor 
heterogeneity in both primary tumor [220] as well as in CTCs [221] was associated with 
emergence of therapy resistance and poor patient outcome. Thus far, however, little is known 
about the extent of genetic heterogeneity and clonal dynamics of DCCs. Reports published in 
the past indicated that DCCs are genomically highly divergent in the early systemic cancer 
and become clonal once metastases have clinical manifested [20,45,46,97]. However, the 
mode of clonal selection is largely unknown. Using the new single-cell aCGH method it was 
possible to get an insight into the microevolution of DCCs over a course treatment of 
metastatic cancer. Genomic analysis revealed the presence of multiple genomically distinct 
DCC clones and showed a complex phylogenetic history of clonal selection with fluctuations 
in the subclonal composition. Interestingly, the detection of two clones (here represented by 
DCC #1 from time point 3 and DCC #2 from time point 4) became possible only after 
initiation of chemotherapy indicating that selective pressure exerted by therapeutic agents 
promoted the selection of previously undetectable genetic variants. Such clonal dynamics 
indicate that chemotherapeutic treatment enhances heterogeneity among DCCs. Strikingly, 
selected clones harboured high proportion of CNAs co-occurring ubiquitously at all stages of 
disease (primary tumor, minimal residual disease and metastases). Therefore, chromosomal 
gains on chromosome 17q and 8q as well as losses on chromosome 6, 12 and 13 can be placed 
on the shared trunk of phylogenetic tree of tumor progression in the tested patient. As such 
these aberrations are likely to represent early somatic alterations that are essential for the 
survival of cancer cells and drive tumor maintenance in the tested patient [215,222]. 
Predominant occurrence of highly recurrent CNAs in the selected DCC clones suggests their 
close relatedness to early tumor progenitor cells. It is likely that a small number of these cells 
survived the clonal sweep and expanded once cancer cells sensitive to chemotherapy have 
been eradicated. A similar pattern of clonal selection was observed during progression from 
myelodysplastic syndromes to secondary acute myeloid leukemia (AML) [223,224]. There, a 
subclone of the tumor founding clone survived therapy, gained additional mutations and 
expanded causing relapse. The collected data indicate that breast cancer DCCs undergo 
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similar process. Unfortunately, from the available data it cannot be elucidated whether 
therapy resistance of arising DCCs clones was a consequence of their intrinsic characteristic 
or whether it was attained by acquisition of protective mutations. Further studies would be 
necessary to test this hypotheses. Alternatively, it may be also possible that survival of the 
DCCs was fostered by phenotes such as clinical dormancy, a state generally associated with 
persistence of micrometastatic cancer cells [225], which confers resistance to 
chemotherapeutic drugs [226]. Recent studies showed that cellular phenotypes have also a 
critical role in development of therapy resistance in breast cancer . However, the interplay 
between genetic and phenotypic diversity in the evolution of chemoresistance is still not well 
understood and requires further investigation [227,228]. Collectively, data from the proof-of-
principle case indicate that the novel single-cell aCGH method is suitable for long term 
monitoring of minimal residual disease and capable of providing important insight about the 
clonal composition of DCCs. 
 
4.4. Utility of the new method in the era of high-throughput sequencing. 
Single-cell WGA products have been analysed with a number of high resolution approaches 
including aCGH, SNP arrays and more recently with NGS. Massive parallel sequencing 
technologies have several advantages over array-based methodologies. In particular, NGS-
based analyses promises genome wide assessment of genetic lesions at base pair resolution. 
Unfortunately, bioinformatic approaches for reliable detection of structural sequence variants 
and base pair substitutions in single-cell WGA products are still at their infancy [121]. Recent 
studies using whole genome or targeted sequencing approaches indicated that reliable calling 
of base pair substitutions (i.e. SNPs or point mutations) in single-cell NGS data requires the 
use of cells harbouring polyploid genomes [154], sequencing of multiple kindred cells of the 
same donor [118,166,229] or application of comparative sequencing strategies necessitating 
additional deep-sequencing of control samples [138]. This limits the utility of single-cell NGS 
as stand-alone tool for sequence analysis of rare and heterogeneous cell populations such as 
DCCs and CTCs. In addition, due to the high costs high-resolution NGS-based analysis is 
practically not feasible to study intratumor genomic heterogeneity in large sample cohorts. 
For this type of analysis low-resolution NGS approaches seem to be more suitable. Recently 
these methodologies have been adapted to study single-cell genomes [142,143,194]. Although 
low-resolution NGS technologies lack the accuracy of deep-sequencing approaches, they still 
allow to assess the genomic heterogeneity at the single-cell level. Still, the level of complexity 
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limits the applicability of this method to large molecular biology laboratories only. In 
contrast, single-cell aCGH assay presented here is relatively simple and cost-efficient. 
Remarkably, the results presented in this thesis show that single-cell aCGH may even be 
competitive to low-resolution NGS in terms of sensitivity. The new single-cell aCGH method 
offers a precise but still affordable solution for screening large number of samples within a 
short period of time. Unlike single-cell NGS, the newly developed aCGH-based approach 
does not require sophisticated infrastructure and complex bioinformatic data evaluation 
allowing its quick implementation in most molecular biology laboratories. Moreover, 
depending on the aim of a given study it can be easily adjusted to the intended use by 
application of customized arrays targeting specific regions of interest. Furthermore, the robust 
design of the new method makes it applicable to a variety of clinical specimens such as FFPE 
tissue samples and immunostained cells. In the future, combination of the new aCGH 
methodology with improved low-error NGS approaches [208] could provide a practicable 
framework for concurrent mapping of copy number and sequence alterations in single cells. 
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5. Summary. 
Metastatic disease is the most common cause of cancer related death. Despite that fact, little is 
known about the processes underlying systemic progression of cancer. Recently, a number of 
studies indicated that cancer cells disseminate early and evolve independent to the primary 
tumor acquiring different oncogenic traits. This results in striking genetic disparity between 
local disease and systemic cancer. Consequently, analysis of resected primary tumor alone is 
insufficient to determine the full complexity of oncogenic changes driving tumorigenic 
progression, emphasizing the need to analyze ectopically residing cancer cells, i.e. single 
DCCs or CTCs. However, currently available methods provided only low-resolution copy 
number information of single-cell genomes. For this reason this thesis aimed to develop a 
high-resolution aCGH for mapping of copy number variations in single-cell genomes. The 
methods utilized the established SCOMP WGA technology and high-resolution 
oligonucleotide DNA arrays. In order to increase the accuracy of single-cell aCGH analysis, 
experimental procedures for DNA labeling and hybridization were optimized to decrease the 
amplification bias and hybridization noise introduced by the WGA. The sensitivity and 
specificity of resulting protocol was validated using single cells of well-characterized cancer 
cell lines and healthy donors showing high concordance with unamplified DNA controls and 
published copy number profiles. Significantly, the new method allowed reproducible 
detection of copy number changes as small as 0.1 Mb in size. Therefore, in comparison with 
previously available methodologies, such as single-cell BAC-based aCGH and mCGH, the 
new protocol allowed to improve the sensitivity by one to two orders of magnitude, 
respectively. Analysis of single DCCs showed that fixation and immunostaining procedures 
used to detect these cells does not have significant impact on the outcome of the new assay, 
showing high robustness the method. The clinical applicability of the new methodology was 
demonstrated in a proof-of-concept study conducted on DCCs from an individual breast 
cancer patient at different time points of high-dose chemotherapy treatment. The analysis 
uncovered co-occurrence of genomically distinct cellular clones among DCCs and revealed 
clonal fluctuations driven by therapeutic selection. Strikingly, the pattern of genomic changes 
detected in DCCs surviving chemotherapy indicated that they originate from genomically less 
advanced cancer cells population. Collectively, this data indicate that the new single-cell 
aCGH assay is a highly sensitive tool capable of inferring the clonal dynamics of 
micrometastatic cells. In the future the new methodology can provide important insights into 
the mechanisms underlying metastatic progression and therapy resistance.
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